Cover Page
Cover Page - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2023 | May 30, 2024 | |
Document Information [Line Items] | ||
Document Type | 10-K | |
Document Annual Report | true | |
Document Period End Date | Dec. 31, 2023 | |
Current Fiscal Year End Date | --12-31 | |
Document Transition Report | false | |
Entity File Number | 001-39128 | |
Entity Registrant Name | Momentus Inc. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 84-1905538 | |
Entity Address, Address Line One | 3901 N. First Street | |
Entity Address, City or Town | San Jose | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 95134 | |
City Area Code | 650 | |
Local Phone Number | 564-7820 | |
Entity Well-known Seasoned Issuer | No | |
Entity Voluntary Filers | No | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Smaller Reporting Company | true | |
Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
ICFR Auditor Attestation Flag | false | |
Document Financial Statement Error Correction [Flag] | true | |
Document Financial Statement Restatement Recovery Analysis [Flag] | false | |
Entity Shell Company | false | |
Entity Public Float | $ 14.3 | |
Entity Common Stock, Shares Outstanding | 16,625,904 | |
Documents Incorporated by Reference | None. | |
Entity Central Index Key | 0001781162 | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | FY | |
Amendment Flag | false | |
Class A common stock | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Class A common stock | |
Trading Symbol | MNTS | |
Security Exchange Name | NASDAQ | |
Warrants | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Warrants | |
Trading Symbol | MNTSW | |
Security Exchange Name | NASDAQ |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2023 | |
Audit Information [Abstract] | |
Auditor Firm ID | 1596 |
Auditor Name | Frank, Rimerman + Co. LLP |
Auditor Location | San Francisco, CA |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 2,118 | $ 61,094 |
Restricted cash, current | 0 | 1,007 |
Insurance receivable | 100 | 4,000 |
Prepaids and other current assets | 8,513 | 10,173 |
Total current assets | 10,731 | 76,274 |
Property, machinery and equipment, net | 3,252 | 4,016 |
Intangible assets, net | 341 | 337 |
Operating right-of-use asset | 5,350 | 6,441 |
Deferred offering costs | 0 | 331 |
Restricted cash, non-current | 373 | 312 |
Other non-current assets | 602 | 4,712 |
Total assets | 20,649 | 92,423 |
Current liabilities: | ||
Accounts payable | 2,805 | 2,239 |
Accrued liabilities | 4,754 | 8,026 |
Loan payable, current | 2,273 | 11,627 |
Contract liabilities, current | 0 | 1,654 |
Operating lease liability, current | 1,268 | 1,153 |
Stock repurchase liability | 0 | 10,000 |
Litigation settlement contingency | 0 | 8,500 |
Other current liabilities | 9 | 27 |
Total current liabilities | 11,109 | 43,226 |
Contract liabilities, non-current | 998 | 1,026 |
Loan Payable, non-current | 0 | 2,404 |
Warrant liability | 3 | 564 |
Operating lease liability, non-current | 4,863 | 6,131 |
Other non-current liabilities | 489 | 465 |
Total non-current liabilities | 6,353 | 10,590 |
Total liabilities | 17,462 | 53,816 |
Commitments and Contingencies (Note 12) | ||
Stockholders’ equity: | ||
Preferred stock, $0.00001 par value; 20,000,000 shares authorized and 0 issued and outstanding as of December 31, 2023 and 2022, respectively | 0 | 0 |
Additional paid-in capital | 376,234 | 342,734 |
Accumulated deficit | (373,047) | (304,127) |
Total stockholders’ equity | 3,187 | 38,607 |
Total liabilities and stockholders’ equity | 20,649 | 92,423 |
Common Class A | ||
Stockholders’ equity: | ||
Common stock, value | 0 | 0 |
Common Class B | ||
Stockholders’ equity: | ||
Common stock, value | $ 0 | $ 0 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | Dec. 31, 2023 | Dec. 31, 2022 |
Preferred stock, par value (in dollars per share) | $ 0.00001 | $ 0.00001 |
Preferred stock, number of shares authorized (in shares) | 20,000,000 | 20,000,000 |
Preferred stock issued (in shares) | 0 | 0 |
Preferred stock outstanding (in shares) | 0 | 0 |
Common Class A | ||
Common stock, par value (in dollars per share) | $ 0.00001 | $ 0.00001 |
Common stock, number of shares authorized (in shares) | 250,000,000 | 250,000,000 |
Common stock issued (in shares) | 8,283,865 | 1,688,824 |
Common stock outstanding (in shares) | 8,283,865 | 1,688,824 |
Common Class B | ||
Common stock, par value (in dollars per share) | $ 0.00001 | $ 0.00001 |
Common stock, number of shares authorized (in shares) | 4,312,500 | 4,312,500 |
Common stock issued (in shares) | 0 | 0 |
Common stock outstanding (in shares) | 0 | 0 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Statement [Abstract] | ||
Revenue from contract with customer, product and service, extensible enumeration | Service [Member] | Service [Member] |
Service revenue | $ 3,089 | $ 299 |
Cost of revenue | 855 | 26 |
Gross profit | 2,234 | 273 |
Operating expenses: | ||
Research and development expenses | 34,351 | 41,721 |
Selling, general and administrative expenses | 36,055 | 49,827 |
Total operating expenses | 70,406 | 91,548 |
Loss from operations | (68,172) | (91,275) |
Other income (expense), net: | ||
Change in fair value of warrant liability | 561 | 5,185 |
Realized loss on disposal of assets | (17) | (168) |
Interest income | 1,225 | 522 |
Interest expense | (2,337) | (5,262) |
Litigation settlement, net | 0 | (4,500) |
Other income (expense) | (180) | 54 |
Total other income (expense), net | (748) | (4,169) |
Net loss | $ (68,920) | $ (95,444) |
Net loss per share, basic (in dollars per share) | $ (23.13) | $ (58.53) |
Net loss per share, diluted (in dollars per share) | $ (23.13) | $ (58.53) |
Weighted average shares outstanding, basic (in shares) | 2,979,845 | 1,630,762 |
Weighted average shares outstanding, fully diluted (in shares) | 2,979,845 | 1,630,762 |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands | Total | Common Class A | Common Stock | Common Stock Common Class A | Additional paid-in capital | Accumulated deficit |
Beginning balance (in shares) at Dec. 31, 2021 | 1,624,236 | |||||
Beginning balance at Dec. 31, 2021 | $ 131,888 | $ 0 | $ 340,571 | $ (208,683) | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Issuance of common stock upon exercise of stock options (in shares) | 43,699 | |||||
Issuance of common stock upon exercise of stock options | 574 | 574 | ||||
Issuance of common stock upon vesting of RSUs (in shares) | 15,741 | |||||
Issuance of common stock upon purchase of ESPP (in shares) | 3,308 | |||||
Issuance of common stock upon purchase of ESPP | 271 | 271 | ||||
Share repurchase related to Section 16 Officer tax coverage exchange (in shares) | (3,723) | |||||
Share repurchase related to Section 16 Officer tax coverage exchange | (331) | (331) | ||||
Stock-based compensation - stock options, RSAs, RSUs | 11,649 | 11,649 | ||||
Share repurchase valuation adjustment | (10,000) | (10,000) | ||||
Shares issued upon exercise of warrant (in shares) | 5,563 | |||||
Net loss | (95,444) | (95,444) | ||||
Ending balance (in shares) at Dec. 31, 2022 | 1,688,824 | 1,688,824 | ||||
Ending balance at Dec. 31, 2022 | $ 38,607 | $ 0 | 342,734 | (304,127) | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Issuance of common stock upon exercise of stock options (in shares) | 10,081 | 10,081 | ||||
Issuance of common stock upon exercise of stock options | $ 130 | 130 | ||||
Issuance of common stock upon vesting of RSUs (in shares) | 42,741 | |||||
Issuance of common stock upon purchase of ESPP (in shares) | 3,131 | |||||
Issuance of common stock upon purchase of ESPP | 33 | 33 | ||||
Share repurchase related to Section 16 Officer tax coverage exchange (in shares) | (4,899) | |||||
Share repurchase related to Section 16 Officer tax coverage exchange | (88) | (88) | ||||
Issuance of common stock and related warrants in registered offering, net of issuance costs (in shares) | 687,920 | |||||
Issuance of common stock and related warrants in registered offering, net of issuance costs | 16,952 | 16,952 | ||||
Issuance of common stock upon exercise of pre-funded warrants (in shares) | 2,216,349 | |||||
Issuance of common stock upon exercise of warrants | 7,881 | 7,881 | ||||
Stock-based compensation - stock options, RSAs, RSUs | 8,480 | 8,480 | ||||
Shares issued upon exercise of warrant (in shares) | 3,577,217 | |||||
Issuance of common stock for consulting services (in shares) | 2,700 | |||||
Issuance of common stock for consulting services | 112 | 112 | ||||
Common stock issued in connection with reverse stock split (in shares) | 59,801 | |||||
Net loss | (68,920) | (68,920) | ||||
Ending balance (in shares) at Dec. 31, 2023 | 8,283,865 | 8,283,865 | ||||
Ending balance at Dec. 31, 2023 | $ 3,187 | $ 0 | $ 376,234 | $ (373,047) |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Cash flows from operating activities: | ||
Net loss | $ (68,920) | $ (95,444) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 894 | 1,090 |
Amortization of debt discount and issuance costs | 1,357 | 2,690 |
Amortization of right-of-use asset | 1,090 | 1,163 |
Change in fair value of warrant liability | (561) | (5,185) |
Impairment of prepaid launch costs | 3,685 | 0 |
Write-off of deferred offering costs | 331 | 0 |
Litigation settlement, net | 0 | 4,500 |
Loss on disposal of fixed and intangible assets | 17 | 168 |
Stock-based compensation expense | 8,480 | 11,580 |
Issuance of common stock for consulting services | 112 | 0 |
Changes in operating assets and liabilities: | ||
Prepaids and other current assets | (565) | (2,206) |
Insurance receivable | 3,900 | 0 |
Other non-current assets | 2,649 | (147) |
Accounts payable | 453 | 373 |
Accrued liabilities | (3,293) | (1,540) |
Accrued interest | (131) | 131 |
Other current liabilities | (14) | (5,020) |
Contract liabilities | (1,681) | 1,126 |
Operating lease liability | (1,153) | (1,189) |
Litigation settlement contingency | (8,500) | 0 |
Other non-current liabilities | 24 | 23 |
Net cash used in operating activities | (61,826) | (87,887) |
Cash flows from investing activities: | ||
Purchases of property, machinery and equipment | (94) | (583) |
Proceeds from sale of property, machinery and equipment | 113 | 34 |
Purchases of intangible assets | (38) | (184) |
Net cash used in investing activities | (19) | (733) |
Cash flows from financing activities: | ||
Proceeds from exercise of stock options | 130 | 574 |
Proceeds from employee stock purchase plan | 33 | 271 |
Proceeds from exercise of warrants | 7,881 | 0 |
Repurchase of Section 16 Officer shares for tax coverage exchange | (88) | (331) |
Principal payments on loan payable | (12,984) | (9,697) |
Payment of deferred offering costs | 0 | (331) |
Payment for repurchase of common shares | (10,000) | 0 |
Proceeds from issuance of common stock and related warrants | 19,000 | 0 |
Payments for issuance costs related to common stock and related warrants | (2,048) | 0 |
Net cash provided by (used in) financing activities | 1,924 | (9,514) |
Decrease in cash, cash equivalents and restricted cash | (59,921) | (98,134) |
Cash, cash equivalents and restricted cash, beginning of year | 62,413 | 160,547 |
Cash, cash equivalents and restricted cash, end of year | 2,492 | 62,413 |
Supplemental disclosure of non-cash investing and financing activities | ||
Purchases of property, machinery and equipment in accounts payable and accrued expenses at period end | 113 | 0 |
Purchases of intangible assets in accounts payable and accrued expenses at year end | 20 | 0 |
Issuance costs related to warrant modification | 2,130 | 0 |
Stock repurchase liability fair value | 0 | 10,000 |
Supplemental disclosure of cash flow information | ||
Cash paid for interest | 980 | 2,440 |
Other Litigation Settlements | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Litigation settlement, net | $ 0 | $ 4,500 |
Nature of Operations
Nature of Operations | 12 Months Ended |
Dec. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Nature of Operations | Note 1. Nature of Operations The Company Momentus Inc. (together with its consolidated subsidiaries “Momentus” or the “Company”) is a U.S. commercial space company that offers satellites, satellite buses, satellite technologies, in-space infrastructure services, including in-space transportation, hosted payloads and in-orbit services. Momentus is making new ways of operating in space possible with its in-space transfer and service vehicles, powered by an innovative, space-proven water plasma-based propulsion system. On May 25, 2022, the Company launched its Vigoride 3 Orbital Service Vehicle (OSV) to Low-Earth Orbit aboard the SpaceX Transporter-5 mission. In addition to Vigoride 3, Momentus used a second port on the same SpaceX mission to fly a third-party deployer from a partner company. Momentus deployed a total of eight customer satellites in low-earth orbit during its inaugural mission, comprising seven satellites from Vigoride 3 and one satellite from the third-party deployer system. The Company incorporated improvements identified during its inaugural mission in advance of its first follow-on mission and other planned follow-on missions. On January 3, 2023, the Company launched Vigoride 5 to low-earth orbit aboard the SpaceX Transporter-6 mission. As of December 31, 2023, the primary mission objectives were completed. On Vigoride’s first orbital pass, Momentus confirmed that both solar arrays were deployed, and the vehicle was generating power and charging its batteries. Momentus demonstrated all spacecraft subsystems through the course of the Vigoride 5 primary mission and identified several deficiencies which have been incorporated into the Vigoride 7 build. Vigoride 5 included testing of our MET propulsion system. Two thrusters were flown and fired over 300 times and 6 hours 58 minutes of accumulated firing time. Vigoride 5 also carried one cubesat that was successfully released into orbit, and a complex hosted payload developed by CalTech to demonstrate technologies needed to collect and beam power to the Earth. Momentus also performed an orbit raise during this mission of over 3 km. Momentus launched its third OSV, Vigoride 6, to low-Earth orbit aboard the SpaceX Transporter-7 mission on April 14, 2023. During the Vigoride-6 mission Momentus deployed all customer payloads. Momentus successfully deployed the REVELA payload for ARCA Dynamics, the VIREO CubeSat for C3S LLC., the DISCO-1 CubeSat for Aarhus University, and the IRIS-C payload for an Asian customer booked through ISILAUNCH. During the Vigoride-6 mission, Momentus also deployed two CubeSats into Low-Earth Orbit as part of the NASA LLITED (Low-Latitude Ionosphere/Thermosphere Enhancements in Density) mission. These two CubeSats, housed behind a single deployer door, were released from the Vigoride OSV earlier than scheduled. While the CubeSats were deployed at the intended altitude of 495km, they were deployed at a different inclination than the intended target orbit needed for the science experiment. Momentus conducted a thorough investigation and identified the root cause as human error in the mapping of a software command. The Company implemented corrective actions to prevent a recurrence. During the Vigoride 6 mission, Momentus conducted a demonstration test of its patented Tape Spring Solar Array (TASSA). This system utilizes flexible solar cell technology, allowing the solar array to be extended and retracted like a tape measure, using its concave shape to provide rigidity. TASSA is designed to be deployed and retracted on orbit numerous times, to be configurable to varying lengths based on power requirements, and utilizes thin film solar cells that are radiation resistant and self-annealing. During its demonstration test on orbit, Momentus was able to demonstrate a significant majority of the major performance requirements for TASSA, including boom yoke deployment, initial roll out deployment, thin film flexible solar cell power generation, low-cost slip ring performance, and retraction, providing confidence as well as identifying areas for improvement, such as processing the metallic substrate to better maintain its intended shape as Momentus continues development of this technology. Other Missions Momentus conducted another mission on the SpaceX Transporter-9 mission launched on November 11, 2023. On this mission, Momentus used a third-party deployer system to deliver payloads into orbit. Momentus supported five payloads for four customers. After launch, the Company confirmed the deployment of the Hello Test 1 and 2 satellites for Hello Space. Momentus was not able to confirm the deployment of the remaining three satellites for three other customers and based on the results of a detailed investigation undertaken, the Company does not believe those satellites were released from the third-party deployer system. Momentus has launched four missions to date, deployed 17 customer satellites, and provided hosted payload services. The Company has produced its next Orbital Service Vehicle, Vigoride 7, that it intends to utilize on a future mission or for use as a satellite bus. In addition to the Vigoride Orbital Service Vehicle, Momentus is now also offering its M-1000 satellite bus which has substantial commonality with Vigoride. With a growing demand for satellite bus services, Momentus is positioned to advance its hardware and flight-proven technology for this market. The M-1000 bus is a flexible option to meet various mission requirements. Innovations to improve sensor capability, maneuverability, increased power, and lower costs are integrated into the product. Momentus believes it can manufacture satellite buses like the M-1000 at a rapid and scalable pace. Momentus has started work in support of its Small Business Innovation Research award from the Space Development Agency. This project's scope involves making tailored modifications to the system underlying the M-1000 satellite bus and Vigoride OSV to support a full range of U.S. Department of Defense (DoD) payloads. Some of these areas include adding a secure payload interface, optical communications terminals, a high-volume data recorder, and improving the modularity of the propulsion system. Business Combination On August 12, 2021, the Company consummated a merger pursuant to the terms of the Agreement and Plan of Merger, dated October 7, 2020, and as amended on March 5, 2021, April 6, 2021, and June 29, 2021 (the “Merger Agreement”), by and among Stable Road Acquisition Corp (“SRAC”), Project Marvel First Merger Sub, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of SRAC (“First Merger Sub”), and Project Marvel Second Merger Sub, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of SRAC (“Second Merger Sub”), pursuant to which First Merger Sub merged with and into Momentus Inc., a Delaware corporation (“Legacy Momentus”) with Legacy Momentus as the surviving corporation of the First Merger Sub, and immediately following which Legacy Momentus merged with and into the Second Merger Sub, with the Second Merger Sub as the surviving entity (the “Business Combination”). In connection with the closing of the Business Combination (“Closing”), the Company changed its name from Stable Road Acquisition Corp. to Momentus Inc., and Legacy Momentus changed its name to Momentus Space, LLC. The Business Combination was accounted for as a reverse recapitalization under ASC Topic 805, Business Combinations , with SRAC and its two wholly-owned subsidiaries. The Company received gross proceeds of $247.3 million upon the closing of the Business Combination. Public and private warrants of SRAC were assumed by the Company as a result of the Business Combination. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these consolidated financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. The Company’s ability to continue as a going concern is dependent on the Company’s ability to successfully raise capital to fund its business operations and execute on its business plan. To date the Company remains heavily focused on growth and continued development of its proprietary technology, and as a result, it has not generated sufficient revenues to provide cash flows that enable the Company to finance its operations internally and the Company’s financial position and operating results raise substantial doubt about the Company’s ability to continue as a going concern. This is reflected by the Company’s incurred a net loss of $68.9 million for the year ended December 31, 2023, and accumulated deficit of $373.0 million as of December 31, 2023. Additionally, the Company used net cash of $61.8 million to fund its operating activities for the year ended December 31, 2023, and had cash and cash equivalents of $2.1 million as of December 31, 2023. Pursuant to the requirements of ASC Topic 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date these consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or are not within control of the Company as of the date the consolidated financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the consolidated financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. In connection with the preparation of the consolidated financial statements for the year ended December 31, 2023, management conducted an evaluation and concluded that there were conditions and events, considered in the aggregate, which raised substantial doubt as to the Company’s ability to continue as a going concern within twelve months after the date of the issuance of such consolidated financial statements. The Company believes that its current level of cash and cash equivalents are not sufficient to fund its regular operations, scaling of commercial production, and maintain its existing services and products. These conditions raise substantial doubt regarding its ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements. In order to proceed with the Company’s business plan and operating strategy, the Company will need to raise substantial additional capital to fund its operations. Until such time, if ever, the Company can generate revenues sufficient to achieve profitability, the Company expects to finance its operations through equity or debt financings, which may not be available to the Company on the timing needed or on terms that the Company deems to be favorable. In an effort to alleviate these conditions, the Company continues to seek and evaluate all opportunities to access additional capital through any available means. As a result of these uncertainties, and notwithstanding management’s plans and efforts to date, there is substantial doubt about the Company’s ability to continue as a going concern. If the Company is unable to raise substantial additional capital in the near term, the Company's operations and business plan will need to be scaled back or halted altogether. Additionally, if the Company is able to raise additional capital but that capital is insufficient to provide a bridge to full commercial production at a profit, the Company's operations could be severely curtailed or cease entirely and the Company may not realize any significant value from its assets. The accompanying consolidated financial statements have been prepared on a going concern basis of accounting. The accompanying consolidated financial statements do not reflect any adjustments that might result if the Company is unable to continue as a going concern. Reverse Stock Split Effective August 22, 2023, the Company’s stockholders approved a 1-for-50 reverse stock split of the Company’s Class A common stock. As a result of the reverse stock split, every 50 shares of Class A common stock issued and outstanding on August 22, 2023, were automatically combined into one share of Class A common stock. Any fractional shares resulting from the reverse stock split were rounded up to the next nearest whole share of Class A common stock. The reverse stock split did not affect the stated par value of the Class A common stock nor did it change the total number of the Company’s authorized shares of Class A common stock. The Company’s Class B common stock was not affected by the reverse stock split. Also on the effective date of the reverse stock split, all options, warrants and other convertible securities of the Company outstanding immediately prior to the reverse stock split were adjusted by dividing the number of shares of Class A common stock into which the options, warrants and other convertible securities are exercisable or convertible by 50 and multiplying the exercise or conversion price thereof by 50, all in accordance with the terms of the plans, agreements or arrangements governing such options, warrants and other convertible securities and subject to rounding to the nearest whole share. Such proportional adjustments were also made to the number of shares and restricted stock units issued and issuable under the Company’s equity compensation plan. The Company has retroactively adjusted all periods presented for the effects of the stock split. See Note 9 for additional information. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Note 2. Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. Reclassification, Change in Presentation and Prior Year Omitted Disclosures Certain prior period amounts in the consolidated financial statements and accompanying notes have been reclassified to conform to the current period’s presentation as follows. Disclosures including the disaggregation of revenue by type (refer to “disaggregation of revenue by type” in this Note), disclosure in segment reporting regarding the long-lived assets by geographic location (refer to “segment reporting” in this Note), the disclosure of Preferred Stock and Class B common stock on the consolidated balance sheet and the disclosure of Class B common stock in Note 9 were omitted from our prior year financials for the year ended December 31, 2022. The disclosures have been included for the year ended December 31, 2023 and include the comparative period for the year ended December 31, 2022. Additionally, there was an immaterial number change related to the disclosure of gross unrecognized tax benefits (refer to “Gross unrecognized tax benefits” in Note 13) for the year-ended December 31, 2022. The Company also adjusted the 2022 federal and state net operating loss (“NOL’s”) carryforwards as the result of the 2023 return to provision true-up that was recorded in relation to the state apportionments (refer to disclosures in Note 13). These adjustments had no impact on the consolidated balance sheets, statements of operations and comprehensive loss, or cash flows as there was no change in the amounts recorded. The Company has determined that these adjustments were immaterial both individually and in aggregate. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other factors it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Accordingly, actual results could differ from those estimates. Significant estimates inherent in the preparation of the consolidated financial statements include, but are not limited to, the timing of revenue recognition, accounting for useful lives of property, machinery and equipment, net, intangible assets, net, accrued liabilities, leases, income taxes including deferred tax assets and liabilities, impairment valuation, stock-based compensation, warrant liabilities, and litigation contingencies. Emerging Growth Company Status Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can choose not to take advantage of the extended transition period and comply with the requirements that apply to non-emerging growth companies, and any such election to not take advantage of the extended transition period is irrevocable. The Company is an “emerging growth company” as defined in Section 2(a) of the Securities Act and has elected to take advantage of the benefits of the extended transition period for new or revised financial accounting standards. The Company will remain an emerging growth company until the earliest of (i) the last day of the fiscal year in which the market value of Class A common stock that is held by non-affiliates exceeds $700 million as of the end of that year’s second fiscal quarter, (ii) the last day of the fiscal year in which the Company after the consummation of the Business Combination has total annual gross revenue of $1.07 billion or more during such fiscal year (as indexed for inflation), (iii) the date on which the Company has issued more than $1 billion in non-convertible debt in the prior three-year period or (iv) December 31, 2024. The Company expects to continue to take advantage of the benefits of the extended transition period, although it may decide to early adopt such new or revised accounting standards to the extent permitted by such standards. This may make it difficult or impossible to compare the Company’s financial results with the financial results of another public company that is either not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition period exemptions because of the potential differences in accounting standards used. Cash and Cash Equivalents Cash and cash equivalents consist of cash on hand, cash in bank with no restrictions, as well as highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities of three months or less when initially purchased. The Company places its cash in the bank, which may at times be in excess of the Federal Deposit Insurance Corporation insurance limits of $250,000 per depositor, with high credit quality financial institutions and attempts to limit the amount of credit exposure with any one institution. Restricted Cash Restricted cash primarily represents deposited cash that is restricted by financial institutions. $0.4 million is restricted primarily as collateral for a letter of credit issued to the Company’s landlord in accordance with the terms of a lease agreement entered into in December 2020, and is classified as a non-current asset as it will be returned to the Company upon the occurrence of future events which are expected to occur beyond one year from December 31, 2023. Deferred Fulfillment and Prepaid Launch Costs The Company prepays for certain launch costs to third-party providers that will carry the transport vehicle to orbit. Prepaid costs allocated to the delivery of a customers’ payload are classified as deferred fulfillment costs and recognized as cost of revenue upon delivery of the customers’ payload. Prepaid costs allocated to our payload are classified as prepaid launch costs and are amortized to cost of sales and research and development expense upon the release of our payload. The allocation is determined based on the distribution between customer and our payload weight on each launch. Due to launch delays and decisions to sell launch spots to third parties, during the year ended December 31, 2023, $3.7 million of prepaid launch costs were written off to research and development operating expenses. As of December 31, 2023, and 2022, the Company had deferred fulfillment and prepaid launch costs of $1.7 million and $7.4 million, respectively, with $1.3 million and $3.0 million recorded within prepaids and other current assets, respectively, and $0.4 million and $4.4 million recorded within other non-current asset, respectively, in our consolidated balance sheets. Property, Machinery and Equipment Property, machinery and equipment are stated at cost less accumulated depreciation. Depreciation is generally recorded using the straight-line method over the estimated useful lives of the respective assets. The estimated useful lives of fixed assets by asset category are described below: Fixed Assets Estimated Useful Life Computer equipment Three years Furniture and fixtures Five years Leasehold improvements Lesser of estimated useful life or remaining lease term (one year to seven years) Machinery and equipment Seven years Costs of maintenance or repairs that do not extend the lives of the respective assets are charged to expenses as incurred. Intangible Assets Intangible assets, which consist of patents, are considered long-lived assets and are reported at cost less accumulated amortization and accumulated impairment loss, if any. Amortization is recognized on a straight-line basis over 10 years for patents, which is the estimated useful lives of the intangible assets. In accordance with ASC Topic 350-40, Intangibles , the Company presents capitalized implementation costs for cloud computing arrangements within prepaid and other current assets, and other non-current assets to properly present the capitalized costs with their related subscription fees. Deferred Offering Costs Offering costs consist of legal, accounting, underwriting fees and other costs incurred that are directly related to fundraising activities. During the years ended December 31, 2023 and 2022, deferred offering costs were attributable to the Company’s S-3 Universal Shelf registration (the “Form S-3”), the at-the-market offering program, and securities purchase agreements entered into during such periods. These costs will be netted with the proceeds proportional to the at-the-market program fundraising and any future fundraising under the "Form S-3". If the Company terminates the Form S-3 or the at-the-market program, or there is a significant delay, all of the deferred offering costs attributed to the Form S-3 or the at-the-market offering program will be immediately written off. Due to the delay in any sales under the at-the-market offering program, during the year ended December 31, 2023, $0.3 million of previously deferred offering costs were written off to other expenses. Refer to Note 9 for additional information. Loss Contingencies The Company estimates loss contingencies in accordance with ASC Sub-Topic 450-20, Loss Contingencies (“ASC 450-20”), which states that a loss contingency shall be accrued by a charge to income if both of the following conditions are met: (i) information available before the consolidated financial statements are issued or are available to be issued indicates that it is probable that a liability had been incurred at the date of the consolidated financial statements and (ii) the amount of loss can be reasonably estimated. We regularly evaluate current information available to us to determine whether such accruals should be adjusted and whether new accruals are required. Refer to Note 12 for additional information. Revenue Recognition The Company enters into short-term contracts for ‘last-mile’ satellite and cargo delivery (transportation service), payload hosting and in-orbit servicing options with customers that are primarily in the aerospace industry. For its transportation service arrangements, the Company has a single performance obligation of delivering the customers’ payload to its designated orbit and recognizes revenue (along with any other fees that have been paid) at a point in time, upon satisfaction of this performance obligation. Additionally, for its in-orbit service arrangements, the Company provides a multitude of services consistently throughout the mission to its customers and also has services available on a ‘stand ready’ basis as needed until the mission reaches its conclusion. The Company recognizes revenue for these in-orbit services ratably over time on a straight-line basis. The Company also enters into contracts to perform analysis and provide engineering services to U.S. Government organizations. The Company accounts for customer contracts in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), which includes the following five-step model: • Identification of the contract, or contracts, with a customer. • Identification of the performance obligations in the contract. • Determination of the transaction price. • Allocation of the transaction price to the performance obligations in the contract. • Recognition of revenue when, or as, the Company satisfies a performance obligation. The Company estimates variable consideration at the most likely amount, which is included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. While the Company’s standard contracts do not contain refund or recourse provisions that enable its customers to recover any non-refundable fees that have been paid, the Company may issue full or partial refunds, or concessions on future services to customers on a case-by-case basis as necessary to preserve and foster future business relationships and customer goodwill. Contracts to provide engineering services to U.S. Government organizations generally have set payments tied to each milestone. When a milestone is achieved, the Company submits the completed service for approval, invoices, and collects on that completed milestone. During the years ended December 31, 2023 and 2022, the Company recorded $0.3 million and $— million of revenue from the U.S. Government, respectively. As part of its contracts with customers, the Company collects up-front non-refundable deposits prior to launch. As of December 31, 2023 and 2022, the Company had customer deposit balances of $1.0 million and $2.7 million, respectively, related to signed contracts with customers, including firm orders and options (some of which have already been exercised by customers). These deposits are recorded as non-current contract liabilities in the Company’s consolidated balance sheets. Included in the collected amount as of December 31, 2023 and 2022, are $1.0 million and $1.0 million, respectively, of non-current deposits. During the year ended December 31, 2023, the Company recognized $3.1 million of revenue, due to transportation services performed in Vigoride 5 and Vigoride 6 spaceship launches, hosted payload services in Vigoride 5, engineering services, and forfeited customer deposits primarily related to expired options. Of the $3.1 million of revenue recognized, $1.8 million was derived from December 31, 2022 contact liability balance. The Company recognized $0.3 million in revenue from transportation services and forfeited customer deposits during the year ended December 31, 2022. The disaggregation of revenue by type is as follows: Year Ended (in thousands) 2023 2022 Transportation services $ 1,582 $ 127 Hosted payload services 568 — Forfeited customer deposits 641 172 Engineering project services 298 — Total revenue $ 3,089 $ 299 Fair Value Measurement The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. A three-tiered hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires that the Company use observable market data, when available, and minimize the use of unobservable inputs when determining fair value: • Level 1, observable inputs such as quoted prices in active markets; • Level 2, inputs other than the quoted prices in active markets that are observable either directly or indirectly; and • Level 3, unobservable inputs in which there is little or no market data, which requires that the Company develop its own assumptions. The fair values of cash and cash equivalents, accounts payable, and certain prepaid and other current assets and accrued expenses approximate carrying values due to the short-term maturities of these instruments which fall with Level 1 of the fair value hierarchy. The carrying value of certain other non-current assets and liabilities approximates fair value. The Company had no Level 2 instruments for the years ended December 31, 2023 and 2022. Certain of the Company’s warrants are recorded as a derivative liability pursuant to ASC Topic 815, Derivatives and Hedging (“ASC Topic 815”), and are classified within Level 3 of the fair value hierarchy as the Company is using the Black Scholes Option Pricing model. The primary significant unobservable input used in the valuation of the warrants is expected stock price volatility. Expected stock price volatility is based on the actual historical volatility of a group of comparable publicly traded companies observed over a historical period equal to the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the warrants. The expected term was based on the maturity of the warrants, which is 5 years. The dividend yield percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. Upon conversion of the Legacy Momentus private warrants immediately prior to the business combination, the key valuation input was the closing price of Company’s Class A common stock on the Closing, as the expected term and volatility were immaterial to the pricing model. The Company’s stock repurchase agreements with the Co-Founders (see Note 12 for additional information) are recorded as contingent liabilities pursuant to ASC Topic 480, measured at fair value. The stock repurchase agreements are classified within Level 3 of the hierarchy as the fair value is dependent on management assumptions about the likelihood of non-market outcomes. The Company paid $10.0 million to satisfy the stock repurchase agreement contingent liabilities during the three months ended March 31, 2023 (see Note 9 for additional information). There were no transfers between levels of input during the years ended December 31, 2023 and 2022. The change in fair values of liabilities subject to recurring remeasurement were as follows: (in thousands) Level Fair value as of December 31, 2022 Payment of Stock Repurchase Liability Change in Fair Value Fair value as of December 31, 2023 Warrant Liability 3 $ 564 $ — $ (561) $ 3 Stock Repurchase Liability 3 10,000 (10,000) — — Total $ 10,564 $ (10,000) $ (561) $ 3 Key assumptions for the Black-Scholes model used to determine the fair value of warrants outstanding as of December 31, 2023 were as follows: Warrant term (years) 2.61 Volatility 113.50 % Risk-free rate 4.05 % Dividend yield 0.00 % Warrant Liability The Company’s private warrants and stock purchase warrants are recorded as derivative liabilities pursuant to ASC Topic 815 and are classified within Level 3 of the fair value hierarchy as the Company is using the Black Scholes Option Pricing model to calculate fair value. See Note 9 for additional information. Significant unobservable inputs, prior to the Company’s stock being publicly listed, included stock price, volatility and expected term. At the end of each reporting period, changes in fair value during the period are recognized as components of other income within the consolidated statements of operations. The Company will continue to adjust the warrant liability for changes in fair value until the earlier of (i) the exercise or expiration of the warrants or (ii) the redemption of the warrants, at which time the warrants will be reclassified to additional paid-in capital within the consolidated statements of stockholders’ equity. The warrants issued by Momentus Inc. prior to the Business Combination were exercised in connection with the Business Combination and as a result, the Company performed a fair value measurement of those warrants on the Closing and recorded the change in the instruments’ fair values prior to converting them to equity. The warrants assumed by the Company as a result of the Business Combination remain outstanding. Public and Private Warrants Prior to the Business Combination, SRAC issued 225,450 private placement warrants (“Private Warrants”) and 172,500 public warrants (“Public Warrants” and, together with the “Private Warrants”, “Public and Private Warrants”). Each whole warrant entitles the holder to purchase one share of the Company’s Class A common stock at a price of $575.00 per share, subject to adjustments and will expire five years after the Business Combination or earlier upon redemption or liquidation. The Private Warrants do not meet the derivative scope exception and are accounted for as derivative liabilities. Specifically, the Private Warrants contain provisions that cause the settlement amounts to be dependent upon the characteristics of the holder of the warrant which is not an input into the pricing of a fixed-for-fixed option on equity shares. Therefore, the Private Warrants are not considered indexed to the Company’s stock and should be classified as a liability. Since the Private Warrants meet the definition of a derivative, the Company recorded the Private Warrants as liabilities on the consolidated balance sheet at fair value upon the Closing, with subsequent changes in the fair value recognized in the consolidated statements of operations at each reporting date. The fair value of the Private Warrants was measured using the Black-Scholes option-pricing model at each measurement date. In addition, the Public Warrants are accounted for as equity classified by the Company. On consummation of the Business Combination, the Company recorded equity related to the Public Warrants of $20.2 million, with an offsetting entry to additional paid-in capital. Similarly, on the consummation of the Business Combination, the Company recorded a liability related to the Private Warrants of $31.2 million, with an offsetting entry to additional paid-in capital. The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC Topic 815, at the initial recognition. Other than the Public and Private Warrants noted above, the Company also had other warrants issued and outstanding which were recognized as derivative liabilities in accordance with ASC Topic 815 until they were fully exercised. Accordingly, the Company recognized the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period until exercised. The fair value of the warrant liabilities issued were initially measured using the Black-Scholes model and were subsequently remeasured at each reporting period with changes recorded as a component of other income in the Company’s consolidated statements of operations. Derivative warrant liabilities are classified as non-current as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. See Note 9 for additional information. Equity Classified Warrants Subsequent to the Business Combination, the Company has issued warrants in conjunction with various securities purchase agreements (See Note 9 for additional information). The warrants are freestanding equity-linked instruments that meet the indexation and equity classification criteria of ASC Sub-Topic 815-40. The grant-date fair value of these warrants is recorded in additional paid-in capital on the consolidated balance sheets. The fair value of the warrants are measured using the Black-Scholes option-pricing model on the grant date. Modification of Equity Classified Warrants A change in the terms or conditions of a warrant is accounted for as a modification. For a warrant modification accounted for under ASC Topic 815, the effect of a modification shall be measured as the difference between the fair value of the modified warrant and the fair value of the original warrant immediately before its terms are modified, with each measured on the modification date. The accounting for incremental fair value of the modified warrants over the original warrants is based on the specific facts and circumstances related to the modification. When a modification is directly attributable to an equity offering, the incremental change in fair value of the warrants is accounted for as an equity issuance cost. When a modification is directly attributable to a debt offering, the incremental change in fair value of the warrants is accounted for as a debt discount or debt issuance cost. For all other modifications, the incremental change in fair value is recognized as a deemed dividend. Basic and Diluted Loss Per Share Net loss per share is provided in accordance with ASC Sub-Topic 260-10, Earnings per Share . Basic net loss per share is computed by dividing losses by the weighted average number of common shares outstanding during the year. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the year. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. See Note 11 for additional information. Impairment of Long-lived Assets The Company evaluates the carrying value of long-lived assets, which includes intangible assets, on an annual basis, or more frequently whenever circumstances indicate a long-lived asset may be impaired. When indicators of impairment exist, the Company estimates future undiscounted cash flows attributable to such assets. In the event cash flows are not expected to be sufficient to recover the recorded value of the assets, the assets are written down to their estimated fair value. During the years ended December 31, 2023 and 2022, there were no impairments of long-lived assets. See Note 4 and Note 5 for additional information. Stock-based Compensation The Company has a stock incentive plan under which equity awards are granted to employees, directors, and consultants. All stock-based payments are recognized in the consolidated financial statements based on their respective grant date fair values. Restricted stock unit fair value is based on our closing stock price on the day of the grant. Stock option fair value is determined using the Black Scholes Merton Option Pricing model. The model requires management to make a number of assumptions, including expected volatility of the Company’s stock, expected life of the option, risk-free interest rate, and expected dividends. Employee Stock Purchase Plan (“ESPP”) compensation fair value is also determined using the Black Scholes Merton Option Pricing model, using a six-month expected term to conform with the six month ESPP offering period. The fair value of equity awards is expensed over the related service period which is typically the vesting period, and expense is only recognized for awards that are expected to vest. The Company accounts for forfeitures as they occur. 401(k) Plan The Company has a 401(k) plan that it offers to its full-time employees. The Company did not contribute to the plan for the years ended December 31, 2023 and 2022. Research and Development Costs Research and development costs are expensed as incurred. Research and development costs include activities to develop existing and future technologies for the Company’s vehicles. Research and development activities include basic research, applied research, design, development, and related test program activities. Costs incurred for developing our vehicles primarily include equipment, material, and labor hours (both internal and subcontractors). Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities related to an executory contractual arrangement are deferred and capitalized. These advance payments are recognized as an expense as the related goods are delivered or services performed. When the related goods are no longer expected to be delivered or services rendered, the capitalized advance payment should be charged to expense. Leases The Company determines if an arrangement contains a lease at inception based on whether there is an identified property, plant or equipment and whether the Company controls the use of the identified asset throughout the period of use. Operating leases are included in the accompanying consolidated balance sheets. Operating lease right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term. Lease liabilities represent the Company’s obligation to make lease payments arising from the lease and are included in current and non-current liabilities. Operating lease ROU assets and lease liabilities are recognized at the lease inception date based on the present value of lease payments over the lease term discounted based on the more readily determinable of (i) the rate implicit in the lease or (ii) the Company’s incremental borrowing rate (which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease). Because the Company’s operating leases generally do not provide an implicit rate, the Company estimates its incremental borrowing rate based on the information available at lease commencement date for borrowings with a similar term. The Company’s operating lease ROU assets are measured based on the corresponding operating lease liability adjusted for (i) payments made to the lessor at or before the commencement date, (ii) initial direct costs incurred and (iii) tenant incentives under the lease. The Company does not assume renewals or early terminations unless it is reasonably certain to exercise these options at commencement. The Company elected the practical expedient which allows the Company to not allocate consideration between lease and non-lease components. Variable lease payments are recognized in the period in which the obligation for those payments is incurred. In addition, the Company elected the practical expedient such that it does not recognize ROU assets or lease liabilities for leases with a term of 12 months or less of all asset classes. Operating lease expense is recognized on a straight-line basis over the lease term. See Note 6 for additional details on the Company’s leases. Income Taxes The Company accounts for income taxes in accordance with authoritative guidance, which requires the use of the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based upon the difference between the financial statement carrying amounts and the tax basis of assets and liabilities and are measured using the enacted tax rate expected to apply to taxable income in the years in which the differences are expected to be reversed. Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, management considers all available evidence, including past operating results, estimates of future taxable income, and the feasibility of tax planning strategies. In the event that management changes its determination as to the amount of deferred tax assets that can be realized, the Company will adjust its valuation allowance with a corresponding impact to the provision for income taxes in the period in which such determination is made. The Company is required to evaluate the tax positions taken in the course of preparing its tax returns to determine whether tax positions are “more-likely-than-not” of being sustained by the applicable tax authority. Tax benefits of positions not deemed to meet the “more likely than not” threshold would be recorded as a tax expense in the current year. The amount recognized is subject to estimate and management judgment with respect to the likely outcome of each uncertain tax position. The amount that is ultimately sustained for an individual uncertain tax position or for all uncertain tax positions in the aggregate could differ from the amount that is initially recognized. Concentrations of Risk Financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and cash equivalents in banks that management believes are creditworthy, however deposits may exceed federally insured limits. Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing operating performance. In consideration of ASC Topic 280, Segment Reporting , we are not organized around specific services or geographic regions. Our chief operating decision maker “CODM” uses financial information to evaluate our performance, which is the same basis on which our results and performance are communicated to our Board of Directors. All of the Company’s long-lived assets are held |
Prepaids and Other Current Asse
Prepaids and Other Current Assets | 12 Months Ended |
Dec. 31, 2023 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Prepaids and Other Current Assets | Note 3. Prepaids and Other Current Assets Prepaids and other current assets consisted of the following: (in thousands) December 31, December 31, Prepaid launch costs, current $ 1,260 $ 3,000 Prepaid research and development 2,415 2,841 Prepaid insurance and other assets 4,838 4,332 Total $ 8,513 $ 10,173 As of December 31, 2023 and 2022, the non-current portion of prepaid launch costs recorded in other non-current assets was approximately $0.4 million and $4.4 million, respectively. |
Property, Machinery and Equipme
Property, Machinery and Equipment | 12 Months Ended |
Dec. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Property, Machinery and Equipment | Note 4. Property, Machinery and Equipment Property, machinery and equipment, net consisted of the following: (in thousands) December 31, December 31, Computer equipment $ 10 $ 10 Leasehold improvements 2,394 2,281 Machinery and equipment 3,411 3,411 Construction in-progress — 106 Property, machinery and equipment, gross 5,815 5,808 Less: accumulated depreciation (2,563) (1,792) Property, machinery and equipment, net $ 3,252 $ 4,016 |
Intangible Assets
Intangible Assets | 12 Months Ended |
Dec. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets | Note 5. Intangible Assets Intangible assets, net consisted of the following as of December 31, 2023: (in thousands) Gross Value Accumulated Amortization Net Value Weighted Average Remaining Amortization Period (In Years) Patents/Intellectual Property $ 519 $ (177) $ 341 6.3 Total $ 519 $ (177) $ 341 Intangible assets, net consisted of the following as of December 31, 2022: (in thousands) Gross Value Accumulated Amortization Net Value Weighted Average Remaining Amortization Period (In Years) Patents/Intellectual Property $ 461 $ (124) $ 337 7.0 Total $ 461 $ (124) $ 337 Amortization expense related to intangible assets was $0.05 million and $0.11 million for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, the future estimated amortization expense related to intangible assets is as follows: (in thousands) 2024 $ 58 2025 58 2026 58 2027 58 2028 49 Thereafter 60 Total $ 341 |
Leases
Leases | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
Leases | Note 6. Leases The Company leases office space under non-cancellable operating leases. In January 2021, the Company commenced a lease in San Jose, California. The lease expires in February 2028. The Company is obligated to pay approximately $10.5 million over the term of the lease. Prior to December 31, 2021, the Company amended two minor leases to extend access until April 2022 to aid the full transition to the San Jose facility. The Company had one additional minor lease that expired in November 2022. The components of operating lease expense were as follows: Year Ended December 31, (in thousands) 2023 2022 Operating lease cost $ 1,470 $ 1,609 Variable lease expense 530 611 Short-term lease expense 62 38 Total lease expense $ 2,062 $ 2,258 Variable lease expense consists of the Company’s proportionate share of operating expenses, property taxes, and insurance. As of December 31, 2023, the weighted-average remaining lease term was 4.2 years and the weighted-average discount rate was 5.6%. As of December 31, 2023, the maturities of the Company’s operating lease liabilities were as follows: (in thousands) 2024 $ 1,580 2025 1,627 2026 1,674 2027 1,729 2028 297 Thereafter — Total lease payments 6,907 Less: Imputed interest (776) Present value of lease liabilities $ 6,131 |
Accrued Liabilities
Accrued Liabilities | 12 Months Ended |
Dec. 31, 2023 | |
Payables and Accruals [Abstract] | |
Accrued Liabilities | Note 7. Accrued Liabilities Accrued expenses consisted of the following: (in thousands) December 31, December 31, Legal and other professional services $ 3,811 $ 3,128 Compensation expense 392 3,584 Research and development projects 323 981 Other accrued liabilities 228 333 Total $ 4,754 $ 8,026 |
Loan Payable
Loan Payable | 12 Months Ended |
Dec. 31, 2023 | |
Debt Disclosure [Abstract] | |
Loan Payable | Note 8. Loan Payable Term Loan On February 22, 2021, the Company entered into a Term Loan and Security Agreement (the “Term Loan”) which provided the Company with up to $40.0 million in borrowing capacity at an annual interest rate of 12%. $25.0 million of the Term Loan was immediately available for borrowing by the Company at the inception of the agreement, the Company borrowed this amount on March 1, 2021. The remaining $15.0 million of borrowing capacity is no longer available as the Company did not achieve certain milestones by the June 30, 2021 deadline. The repayment terms of the Term Loan provide for interest-only payments from March 1, 2021 through February 28, 2022. Under the original terms, the principal amount was due and payable on March 1, 2022. However, during January 2022 the Company exercised its option to pay back the principal amount of the Term Loan over two years beginning on March 1, 2022 and ending on February 28, 2024. The Company allocated the proceeds from the Term Loan agreement to the note and warrants issued in conjunction with the Term Loan comprising the financing agreement based on the relative fair value of the individual securities on the February 22, 2021 closing date of the agreements. The discount attributable to the note, an aggregate of $15.8 million, primarily related to the value of the warrant liability with immaterial issuance costs, is amortized using the effective interest method over the term of the note, originally maturing on March 1, 2022, but now being repaid over two years, recorded as interest expense. Because the discount on the note exceeds 63% of its initial face value, and because the discount is amortized over the period from issuance to maturity, the calculated effective interest rate up until January 2022 was 126.0%. As a result of the exercised extended repayment schedule, the unamortized discount and issuance costs were recast over the updated term of the loan and resulted in a recalculated effective interest rate of 28.2%. Interest expense amortization was $1.4 million and $2.7 million, for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, the Company’s total loan payable consisted of gross Term Loan payable of $2.3 million offset by unamortized debt discount and issuance costs of $45.7 thousand. The Term Loan principal has future scheduled maturities of $2.3 million for 2024. |
Stockholders_ Equity
Stockholders’ Equity | 12 Months Ended |
Dec. 31, 2023 | |
Equity [Abstract] | |
Stockholders’ Equity | Note 9. Stockholders' Equity Common Stock and Preferred Stock Effective August 22, 2023, the Company’s stockholders approved a 1-for-50 reverse stock split of the Company’s Class A common stock. As a result of the reverse stock split, every 50 shares of Class A common stock issued and outstanding on August 22, 2023, were automatically combined into one share of Class A common stock. Any fractional shares resulting from the reverse stock split were rounded up to the next nearest whole share of Class A common stock. To effectuate the reverse stock split, the Company filed a certificate of amendment to the Second Amended and Restated Certificate of Incorporation. As a result of the reverse stock split, there was no change to par value and the total number of authorized shares of Class A common stock. Pursuant to the terms of the Second Amended and Restated Certificate of Incorporation, as amended, the Company is authorized and has available a total of 274,312,500 shares of stock, consisting of (i) 250,000,000 shares of Class A common stock, par value $0.00001 per share, (ii) 4,312,500 shares of Class B common stock, par value $0.00001 per share, and (iii) 20,000,000 shares of preferred stock, par value $0.00001 per share. Warrant Inducement Agreement On November 6, 2023, the Company entered into a warrant inducement agreement with an investor. Pursuant to the warrant inducement agreement, the Company agreed to issue new warrants to purchase up to 5,808,538 shares of the Company’s Class A common stock, with a strike price of $3.86 per share (the “November Warrants”), in consideration of the investor’s agreement to exercise the 672,948, 231,321, and 2,000,000 of Series A Warrants, February Class A Warrants, and October Warrants, respectively. The November Warrants will be exercisable immediately after issuance and will expire five years from the date of issuance. The transactions contemplated by the warrant inducement agreement closed on November 9, 2023. The Company estimated the fair value of the November Warrants using the Black-Scholes valuation model. The significant inputs into the Black-Scholes valuation model at the initial recognition date are as follows: November Warrants Warrant term (years) 5.00 Volatility 86.00 % Risk-free rate 4.60 % Dividend yield 0.00 % In connection with the warrant inducement agreement, on November 9, 2023 when the transaction closed, the investor paid gross proceeds of approximately $6.5 million, before deducting offering fees and other expenses of $0.5 million payable by the Company, representing the exercise price of $2.00 per share for the 2,904,269 shares of Class A common stock issuable upon the exercise of the Series A Warrants, February Class A Warrants, and October Warrants (collectively, the “Induced Warrants”), plus an additional $0.25 consideration per share. Net proceeds of $6.0 million from the exercise of the Induced Warrants was recorded to additional paid-in capital. The additional $0.25 of consideration per share represented a modification of the Induced Warrants. The Company estimated the fair value of the Induced Warrants immediately before and after modification using the Black-Scholes valuation model and determined an incremental increase in fair value of approximately $0.5 million. In accordance with ASC Topic 815 guidance on equity classified warrant modifications, the incremental change in fair value of the Induced Warrants was accounted for as an additional equity issuance cost for the warrant inducement, which was recorded to additional paid-in capital. The significant inputs into the Black-Scholes valuation model before and after the modification date are as follows: Induced Warrants Before Modification After Modification Warrant term (years) 4.91 4.91 Volatility 89.00 % 89.00 % Risk-free rate 4.55 % 4.55 % Dividend yield 0.00 % 0.00 % On November 8, 2023, only 1,188,269 shares of Class A common stock were delivered to the investor due to beneficial ownership limitations on the exercise of the Series A Warrants, February Class A Warrants and October Warrants. The remaining 1,716,000 shares were subsequently delivered to the investor, in accordance with the beneficial ownership limitations in the respective warrant agreements, during the year ended December 31, 2023. October 2023 Securities Purchase Agreement On October 2, 2023, the Company entered into a Securities Purchase Agreement (the “October SPA”) with an investor, pursuant to which the Company issued and sold to the investor in a registered direct offering (the “October Offering”), (i) an aggregate of 290,000 shares of the Company’s Class A common stock at a purchase price of $2.00 per share, (ii) pre-funded warrants (the “October Pre-Funded Warrants”) to purchase an aggregate of 1,710,000 shares of Class A common stock and (iii) warrants to purchase 2,000,000 shares of Class A common stock (the “October Warrants”). The purchase price of each October Pre-Funded Warrant was equal to the price per share of Class A common stock being sold in the Offering minus $0.00001. The October Pre-Funded Warrants have an exercise price of $0.00001 per share and are exercisable at any time after the issuance, subject to the availability of authorized but unissued shares of Class A common stock, and will not expire until exercised. The October Warrants have an exercise price of $2.00 and are exercisable at any time after issuance, subject to the availability of authorized but unissued shares of Class A common stock. The October Warrants will expire five years from the date of issuance. The Company received aggregate gross proceeds from the October Offering of approximately $4.0 million, before deducting estimated issuance costs of $0.4 million, in connection with the October Offering. Net proceeds of $3.6 million from the October Offering was recorded to additional paid-in capital. Both the October Pre-Funded Warrants and the October Warrants met the requirements for equity classification. The Company estimated the fair value of the October Pre-Funded Warrants based on the fair value of the Company’s Class A common stock on the issuance date, less the $0.00001 exercise price. The Company estimated the fair value of the October Warrants using the Black-Scholes valuation model. The significant inputs into the Black-Scholes valuation model at the initial recognition date are as follows: October Warrants Warrant term (years) 5.00 Volatility 92.00 % Risk-free rate 4.67 % Dividend yield 0.00 % In connection with the October Offering, the Company also agreed to amend each of the Series A Warrants, Series B Warrants, and February Class A Warrants (collectively, the “Modified Warrants”) to purchase up to an aggregate of 672,948, 672,948, and 231,321 shares of Class A common stock, respectively, at an exercise price of $7.18 per share. Prior to amendment, the Series A Warrants and February Class A Warrants had a termination date of September 11, 2028 and the Series B Warrants had a termination date of September 11, 2024. Upon amendment, each of the Series A Warrants, Series B Warrants, and February Class A Warrants will have a reduced exercise price of $2.00 per share and a termination date of October 4, 2028. The Company estimated the fair value of the Modified Warrants immediately before and after modification using the Black-Scholes valuation model and determined an incremental increase in fair value of approximately $1.0 million. In accordance with ASC Topic 815 guidance on equity classified warrant modifications, the incremental change in fair value of the Modified Warrants was accounted for as an additional equity issuance cost for the October Offering, which was recorded to additional paid-in capital. The significant inputs into the Black-Scholes valuation model before and after the modification date are as follows: Before Modification After Modification February Class A Warrants and Series A Warrants Series B Warrants Modified Warrants Warrant term (years) 4.94 0.95 5.01 Volatility 88.00 % 86.00 % 89.00 % Risk-free rate 4.55 % 5.39 % 4.67 % Dividend yield 0.00 % 0.00 % 0.00 % On October 4, 2023, the Company issued 672,948 shares of Class A common stock as a result of the exercise of the Series B Warrants and received cash proceeds of approximately $1.3 million. Subsequent to the October Offering, during the year ended December 31, 2023, the Company issued 1,710,000 shares of Class A common stock as a result of all of the October Pre-Funded Warrants being exercised and the Company received an immaterial amount of cash proceeds. September 2023 Securities Purchase Agreement On September 7, 2023, the Company entered into a Securities Purchase Agreement (the “September SPA”) with an investor, pursuant to which the Company issued and sold to the investor in a registered offering (the “September Offering”), (i) an aggregate of 210,000 shares of the Company’s Class A common stock at a purchase price of $7.43 per share, (ii) pre-funded warrants (the “September Pre-Funded Warrants”) to purchase an aggregate of 462,948 shares of Class A common stock and (iii) Series A warrants to purchase 672,948 shares of Class A common stock (the "Series A Warrants"), and (iv) Series B warrants to purchase 672,948 shares of Class A common stock (the "Series B Warrants" together with the Series A Warrants, the "September Warrants"). The purchase price of each September Pre-Funded Warrant was equal to the price per share of Class A common stock being sold in the Offering minus $0.00001. The September Pre-Funded Warrants have an exercise price of $0.00001 per share and are exercisable at any time after the issuance, subject to the availability of authorized but unissued shares of Class A common stock, and will not expire until exercised. The September Warrants have an exercise price of $7.18 and are exercisable at any time after issuance, subject to the availability of authorized but unissued shares of Class A common stock. 672,948 of the September Warrants will expire on September 11, 2028 (the Series A Warrants) and 672,948 of the September Warrants will expire on September 11, 2024 (the Series B Warrants). The Company received aggregate gross proceeds from the September Offering of approximately $5.0 million, before deducting estimated issuance costs of $0.4 million, in connection with the September Offering. Net proceeds of $4.6 million from the September Offering was recorded to additional paid-in capital. Both the September Pre-Funded Warrants and the September Warrants met the requirements for equity classification. The Company estimated the fair value of the September Pre-Funded Warrants based on the fair value of the Company’s Class A common stock on the issuance date, less the $0.00001 exercise price. The Company estimated the fair value of the September Warrants using the Black-Scholes valuation model. The significant inputs into the Black-Scholes valuation model at the initial recognition date are as follows: Series A Warrants Series B Warrants Warrant term (years) 5.00 1.00 Volatility 85.00 % 79.00 % Risk-free rate 4.35 % 5.33 % Dividend yield 0.00 % 0.00 % In connection with the September Offering, the Company also agreed to amend the February Class A Warrants to purchase up to an aggregate of 231,321 shares of Class A common stock at an exercise price of $57.50 per share with a termination date of August 27, 2028 (see discussion of the February Offering below). Upon amendment, the February Class A Warrants exercise price was reduced to $7.18 per share and the termination date was extended to September 11, 2028. The Company estimated the fair value of the February Class A Warrants immediately before and after modification using the Black-Scholes valuation model and determined an incremental increase in fair value of approximately $0.6 million. In accordance with ASC Topic 815 guidance on equity classified warrant modifications, the incremental change in fair value of the February Class A Warrants was accounted for as an additional equity issuance cost for the September Offering, which was recorded to additional paid-in capital. The significant inputs into the Black-Scholes valuation model before and after the modification date are as follows: Before Modification After Modification Warrant term (years) 4.97 5.01 Volatility 84.00 % 85.00 % Risk-free rate 4.40 % 4.33 % Dividend yield 0.00 % 0.00 % Subsequent to the September Offering, during the year ended December 31, 2023, the Company issued 462,948 shares of Class A common stock as a result of all of the September Pre-Funded Warrants being exercised and the Company received an immaterial amount of cash proceeds. February 2023 Securities Purchase Agreement On February 23, 2023, the Company entered into a Securities Purchase Agreement (the “February SPA”) with an investor, pursuant to which the Company issued and sold to the investor in a registered offering (the “February Offering”), (i) an aggregate of 187,920 shares of the Company’s Class A common stock at a purchase price of $43.23 per share, (ii) pre-funded warrants (the “February Pre-Funded Warrants”) to purchase an aggregate of 43,401 shares of Class A Stock and (iii) warrants to purchase 231,321 shares of Class A Stock (the “February Class A Warrants”). The purchase price of each February Pre-Funded Warrant was equal to the price per share of Class A common stock being sold in the February Offering minus $0.00001. The February Pre-Funded Warrants have an exercise price of $0.00001 per share and are exercisable at any time after the issuance, subject to the availability of authorized but unissued shares of Class A common stock, and will not expire until exercised. The February Class A Warrants have an exercise price of $57.50 per share and exercisable beginning on August 27, 2023, subject to the availability of authorized but unissued shares of Class A common stock, and will expire August 27, 2028. The Company received aggregate gross proceeds from the February Offering of approximately $10.0 million, before deducting estimated issuance costs of $0.7 million, in connection with the February Offering. Net proceeds of $9.3 million from the February Offering was recorded to additional paid-in capital. Both the February Pre-Funded Warrants and the February Class A Warrants met the requirements for equity classification. The Company estimated the fair value of the February Pre-Funded Warrants based on the fair value of the Company’s Class A common stock on the issuance date, less the $0.00001 exercise price. The Company estimated the fair value of the February Class A Warrants using the Black-Scholes valuation model. The significant inputs into the Black-Scholes valuation model at the initial recognition date are as follows: Warrant term (years) 5.51 Volatility 85.00 % Risk-free rate 4.03 % Dividend yield 0.00 % Subsequent to the February SPA, during the year ended December 31, 2023, the Company issued 43,401 shares of Class A common stock as a result of all of the February Pre-Funded Warrants being exercised and the Company received an immaterial amount of cash proceeds. Co-Founder Divestment and Stock Repurchase Agreements In accordance with the NSA and pursuant to stock repurchase agreements entered into with the Company, the Co-Founders sold 100% of their respective equity interests in the Company on June 30, 2021. The Company paid an aggregate of $40.0 million to the Co-Founders following the Business Combination, and an additional payment of an aggregate of $10.0 million was payable after cumulative business combination or capital raising transactions resulted in cash proceeds to the Company of no less than $250.0 million. As a result of the February Offering on February 27, 2023, the Company raised $10.0 million of gross cash proceeds through the sale of securities which, together with the $247.3 million raised in the Business Combination and other capital raising activities, triggered the $10.0 million obligation under the stock repurchase agreements. In March 2023, the Company paid the Co-Founders $10.0 million to pay off the liability. Public and Private Warrants As of December 31, 2023, the Company had Public and Private Warrants outstanding to purchase 172,500 shares and 225,450 shares of Class A common stock, respectively, related to the Business Combination. The warrants entitle the registered holder to purchase stock at a price of $575.00 per share, subject to adjustment, at any time commencing on August 12, 2021. The Public and Private Warrants expire on the fifth anniversary of the Business Combination, or earlier upon redemption or liquidation. The Company also had private warrants outstanding to purchase 6,171 shares of Class A common stock, with an exercise price of $10.00 per share, unrelated to the Business Combination, which were exercised on a net basis for 5,563 shares during the three months ended March 31, 2022. The Private Warrants assumed in connection with the Business Combination are accounted for as a derivative liability and a decrease of the estimated fair value of the warrants of $0.6 million and $5.2 million for the years ended December 31, 2023 and 2022, respectively, was recorded in other income (expense) within the consolidated statements of operations. The Public Warrants and the legacy outstanding Private Warrants were recorded as equity within the consolidated statements of stockholders’ equity. Contingent Sponsor Earnout Shares As a result of the Business Combination, the Company modified the terms of 28,750 shares of Class A common stock held by SRAC’s sponsor (the “Sponsor Earnout Shares”), such that all such shares will be forfeited if the share price of Class A common stock does not reach a volume-weighted average closing sale price of $625.00, two thirds of such shares will be forfeited if the share price of Class A common stock does not reach a volume-weighted average closing sale price of $750.00, and one third of such shares will be forfeited if the share price of Class A common stock does not reach a volume-weighted average closing sale price of $875.00, in each case, prior to the fifth anniversary of the Business Combination. Certain events which change the number of outstanding shares of Class A common stock, such as a split, combination, or recapitalization, among other potential events, will equitably adjust the target vesting prices above. The Sponsor Earnout Shares may not be transferred without the Company’s consent until the shares vest. The Sponsor Earnout Shares are recorded within equity. Due to the contingently forfeitable nature of the shares, the Sponsor Earnout Shares are excluded from basic EPS calculations but are considered potentially dilutive shares for the purposes of diluted EPS (refer to Note 11). At-The-Market Offering On September 28, 2022, Momentus entered into an At-the-Market Equity Offering Sales Agreement with a sales agent (the “ATM Sales Agreement”). Pursuant to the ATM Sales Agreement, the Company may from time to time sell, through the sales agent using at-the-market (“ATM”) offerings, shares of Class A common stock up to an aggregate offer price of $50.0 million. Under the ATM Sales Agreement, the sales agent will be entitled to compensation at a commission rate of up to 3.0% of the gross sales price per share sold. During the year ended December 31, 2023 there were no sales under the ATM Sales Agreement. Due to the delay in any sales under the at-the-market offering program, during the year ended December 31, 2023, $0.3 million of previously deferred offering costs were written off to other expenses. |
Stock-based Compensation
Stock-based Compensation | 12 Months Ended |
Dec. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Stock-based Compensation | Note 10. Stock-based Compensation Legacy Stock Plans In May 2018, the Board of Directors of Momentus Inc. approved the 2018 Stock Plan (the “Initial Plan”) that allowed for granting of incentive and non-qualified stock options and restricted stock awards to employees, directors, and consultants. The Initial Plan was terminated in November 2018. Awards outstanding under the Initial Plan continue to be governed by the terms of the Initial Plan. In February and March 2020, the Board approved the Amended and Restated 2018 Stock Plan (the “2018 Plan”). No additional grants have been made since 2020 and no new grants will be made from the 2018 Plan, however, the options issued and outstanding under the plan continue to be governed by the terms of the 2018 Plan. Forfeitures from the legacy plans become available under the 2021 Equity Incentive Plan, described below. 2021 Equity Incentive Plan In connection with the Closing of the SPAC transaction, the Company adopted the 2021 Equity Incentive Plan (the “2021 Plan”), under which 119,658 shares of Class A common stock were initially reserved for issuance. The 2021 Plan allows for the issuance of incentive stock options (“ISOs”), non-qualified stock options (“NSOs”), restricted stock awards (“RSAs”), stock appreciation rights (“SARs”), restricted stock units (“RSUs”), and performance awards. The Board of Directors determines the period over which grants become exercisable. The 2021 Plan became effective immediately following the Closing. The 2021 Plan has an evergreen provision which allows for shares available for issuance under the plan to be increased on the first day of each fiscal year beginning with the 2022 fiscal year and ending on (and including) the first day of the 2031 fiscal year, in each case, in an amount equal to the lesser of (i) three percent (3.0%) of the outstanding shares on the last day of the immediately preceding fiscal year and (ii) such number of Shares determined by the Board. During the year ended December 31, 2023, the shares available for grant under the 2021 Plan increased by 50,664 and 7,473 due to the evergreen provision and forfeitures from both the Initial Plan and the 2018 Plan, respectively. As of December 31, 2023, there were 45,721 shares remaining available for grant. Grant activity under the 2021 Plan is described below. 2021 Employee Stock Purchase Plan In connection with the Closing, the Company adopted the Employee Stock Purchase Plan (the “2021 ESPP Plan”), under which 31,909 shares of Class A common stock were initially reserved for issuance. The Plan provides a means by which eligible employees of the Company may be given an opportunity to purchase shares of Class A common stock at a discount as permitted under the Internal Revenue Code of 1986, as amended. The 2021 ESPP Plan has an evergreen provision which allows for shares available for issuance under the plan to be increased on the first day of each fiscal year beginning with the 2022 fiscal year and ending on (and including) the first day of the 2031 fiscal year, in each case, in an amount equal to the lesser of (i) half a percent (0.5%) of the outstanding shares on the last day of the calendar month prior to the date of such automatic increase and (ii) 31,909 shares. The 2021 ESPP Plan became effective immediately following the Closing. During the year ended December 31, 2023, the shares available for issuance under the 2021 ESPP Plan increased by 8,444 due to the evergreen provision. During the year ended December 31, 2023, there were 3,230 shares issued under the 2021 ESPP Plan. The Company has an outstanding liability pertaining to the ESPP of $13.6 thousand as of December 31, 2023, included in accrued expenses, for employee contributions to the 2021 ESPP Plan, pending issuance at the end of the offering period. As of December 31, 2023, there were 41,936 shares remaining available for issuance. 2022 Inducement Equity Plan In February 2022, the Company adopted the 2022 Inducement Equity Plan (the “2022 Plan”), under which 80,000 shares of Class A common stock were initially reserved for issuance. The 2022 Plan allows for the issuance of NSOs, RSAs, SARs, RSUs, and stock bonus awards, subject to certain eligibility requirements. The Board of Directors determines the period over which grants become exercisable and grants generally vest over a four-year period. On March 22, 2023, the Company adopted the first amendment to the 2022 Plan to increase the number of shares of Class A common stock available for issuance under the 2022 Plan from 80,000 shares of Class A common stock to 140,000 shares of Class A common stock. All other terms of the 2022 Plan remained the same. On May 8, 2023, the Company adopted the second amendment to the 2022 Plan to increase the number of shares of Class A common stock available for issuance under the 2022 Plan from 140,000 shares of Class A common stock to 160,000 shares of Class A common stock. All other terms of the 2022 Plan remained the same. As of December 31, 2023, only RSU grants have been made under the 2022 Plan and there were 60,952 shares remaining available for issuance. Grant activity under the 2022 Plan is described below. Options Activity The following table sets forth the summary of options activity, under the 2018 Plan and the 2021 Plans, for the year ended December 31, 2023: (in thousands, except share-based data) Total Options Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Term (In Years) Aggregate Intrinsic Value Outstanding as of December 31, 2022 51,166 $ 60.69 Vested exercised (10,081) $ 12.95 Forfeitures (17,173) $ 77.95 Outstanding as of December 31, 2023 23,912 $ 68.39 7.1 $ — Exercisable as of December 31, 2023 18,705 $ 54.36 6.8 $ — Vested and expected to vest as of December 31, 2023 23,912 $ 68.39 7.1 $ — As of December 31, 2023, there was a total of $0.3 million in unrecognized compensation cost related to unvested options, which is expected to be recognized over a weighted-average period of 1.1 years. The total intrinsic value of options exercised during the years ended December 31, 2023 and 2022 was $0.2 million and $5.1 million, respectively. Restricted Stock Unit and Restricted Stock Award Activity The following table sets forth the summary of RSU and RSA activity, under the Initial Plan, the 2018 Plan, the 2021 Plan, and the 2022 Plan, for the year ended December 31, 2023. RSAs were an immaterial portion of activity for the period: Shares Weighted Average Grant Date Fair Value (i.e. Share Price) Outstanding as of December 31, 2022 155,573 $ 199.74 Granted 212,089 27.26 Vested (42,701) 202.28 Forfeited (105,241) 86.95 Outstanding as of December 31, 2023 219,720 $ 86.78 As of December 31, 2023, there was a total of $14.1 million in unrecognized compensation cost related to unvested RSUs, which is expected to be recognized over a weighted-average period of 1.3 years. Outstanding unvested and expected to vest RSUs had an intrinsic value of $0.4 million. Stock-based Compensation The following table sets forth the stock-based compensation under the Initial Plan, the 2018 Plan, the 2021 Plan, and the 2022 Plan by expense type: Year Ended December 31, (in thousands) 2023 2022 Research and development expenses $ 2,131 $ 2,134 Selling, general and administrative expenses 6,349 9,446 Total $ 8,480 $ 11,580 The following table sets forth the stock-based compensation under the Initial Plan, the 2018 Plan, the 2021 Plan, and the 2022 Plan by award type: Year Ended December 31, (in thousands) 2023 2022 Options $ 352 $ 538 RSUs & RSAs 8,115 10,995 ESPP 13 117 Performance Awards — (70) Total $ 8,480 $ 11,580 Performance Awards Performance awards under the 2021 Plan are accounted for as liability-classified awards, as the obligations are typically a fixed monetary amount which is settled on a future date in a variable number of shares of the Company’s Class A common stock. The variable number of potentially settled shares is not limited. Performance awards are measured at their fair value based on management’s estimates of potential outcomes of the performance. Outstanding performance awards correspond to zero shares if they were settled on December 31, 2023. Issuance of Common Stock to Non-employees During the year ended December 31, 2023, the Company issued 2,700 shares of the Company’s Class A common stock to a third party consulting firm in exchange for public relations services. The shares were not issued under the equity incentive plans described above. Under the agreement, the shares are contingently forfeitable in the event of early termination by the Company. The shares had an issuance date fair value of $0.1 million to be recorded as consulting expense over the six-month term of the agreement. Related consulting expense of $0.1 million was recognized during the six months ended June 30, 2023. The Company issued no shares to non-employees in the current quarter. |
Earnings Per Share
Earnings Per Share | 12 Months Ended |
Dec. 31, 2023 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | Note 11. Earnings Per Share Net Loss Per Share Net loss per share is provided in accordance with ASC Sub-Topic 260-10, Earnings Per Share . Basic earnings per share is computed by dividing net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted earnings per share gives effect to all dilutive potential common shares outstanding during the period. It is computed by dividing undistributed earnings allocated to common stockholders for the period by the weighted average number of common shares outstanding during the period, plus the dilutive effect of outstanding preferred shares, options and unvested stock units, and warrants outstanding pursuant to the treasury stock method. As the Company incurred a net loss for the years ended December 31, 2023 and 2022, the inclusion of certain options, unvested stock units, warrants, and contingent Sponsor Earnout Shares in the calculation of diluted earnings per share would be anti-dilutive and, accordingly, were excluded from the diluted loss per share calculation. The following table summarizes potential common shares that were excluded as their effect is anti-dilutive: Year Ended December 31, 2023 2022 Options and unvested stock units outstanding 243,911 127,116 Warrants outstanding 6,206,488 399,149 Contingent Sponsor Earnout Shares 28,750 28,750 Total 6,479,149 555,015 |
Commitment and Contingencies
Commitment and Contingencies | 12 Months Ended |
Dec. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Note 12. Commitments and Contingencies Purchase Obligations Momentus enters into purchase obligations in the normal course of business. These obligations include purchase orders and agreements to purchase goods or services that are enforceable, legally binding, and have significant terms and minimum purchases stipulated. As of December 31, 2023, the Company’s future unconditional purchase obligations are as follows: (in thousands) 2024 $ 2,597 Total $ 2,597 Legal Proceedings Securities Class Actions On July 15, 2021, a purported stockholder of SRAC filed a putative class action complaint against SRAC, SRC-NI Holdings, LLC ("Sponsor"), Brian Kabot (SRAC CEO), James Norris (SRAC CFO), Momentus, and the Company's co-founder and former CEO, Mikhail Kokorich, in the United States District Court for the Central District of California, in a case captioned Jensen v. Stable Road Acquisition Corp., et al. , No. 2:21-cv-05744 (the " Jensen class action"). The complaint alleges that the defendants omitted certain material information in their public statements and disclosures regarding the Business Combination, in violation of the securities laws, and seeks damages on behalf of a putative class of stockholders who purchased SRAC stock between October 7, 2020 and July 13, 2021. Subsequent complaints captioned Hall v. Stable Road Acquisition Corp., et al. , No. 2:21-cv-05943 and Depoy v. Stable Road Acquisition Corp., et al. , No. 2:21-cv-06287 were consolidated in the first filed matter (collectively, referred to as the "Securities Class Actions"). An amended complaint was filed on November 12, 2021. The Company disputes the allegations in the Securities Class Actions. On February 10, 2023, the lead plaintiff in the Securities Class Actions and the Company reached an agreement in principle to settle the Securities Class Actions. Under the terms of the agreement in principle, the lead plaintiff, on behalf of a class of all persons that purchased or otherwise acquired Company stock between October 7, 2020 and July 13, 2021, inclusive, would release the Company from all claims asserted or that could have been asserted in the Securities Class Actions and dismiss such claims with prejudice, in exchange for payment of $8.5 million by the Company (at least $4.0 million of which was funded by insurance proceeds). On April 10, 2023, the parties filed a Notice of Settlement with the Court, and on August 18, 2023, the parties executed a Settlement Agreement. On August 30, 2023 the lead plaintiff filed a Motion for Preliminary Approval of Class Action Settlement, and the Court entered an Order Preliminarily Approving Settlement and Providing for Notice on September 21, 2023. Pursuant to that Order, on October 5, 2023, the Company paid $1.0 million into the settlement escrow account. On November 16, 2023, following the Court’s order granting lead plaintiff’s motion to enforce the settlement agreement and despite the Company’s attempts to negotiate an extension of time to satisfy its payment obligations, the Company paid an additional $3.5 million into the settlement escrow account. Insurance carriers made additional payments totaling $4.0 million into the settlement escrow account. On April 23, 2024, the Court entered an order and judgment finally approving the settlement of the Securities Class Actions. A group of plaintiffs asserting the Delaware Class Actions (see below) objected to the scope of the release in the settlement, and the Court overruled the objection. Those objectors may or may not appeal the Court’s decision to overrule their objections and approve the settlement. The Company does not know the timing of when such an appeal, if filed, would be heard. If the objectors do not appeal the approval of the settlement, or if their appeal is ultimately rejected by the Court of Appeal, then the settlement will resolve all claims in the Securities Class Actions against the Company (except as to any shareholders that may elect to opt-out of the class). The Company and the other defendants have denied and continue to deny each and all of the claims alleged in the Securities Class Actions, and the proposed settlement contains no admission of liability, wrongdoing or responsibility by any of the defendants. In the event that a court, on appeal or otherwise, overturns the approval of the settlement, the Company will continue to vigorously defend against the claims asserted in the Securities Class Actions. As a result of the agreement to settle the Securities Class Action, the Company recorded a litigation settlement contingency of $8.5 million. The Company additionally recorded an insurance receivable of $4.0 million for the insurance proceeds expected from its insurers related to the settlement. The net amount of $4.5 million was recognized in litigation settlement, net during the year ended December 31, 2022. CFIUS Review In February 2021, the Company and Mikhail Kokorich submitted a joint notice to the CFIUS for review of the historical acquisition of interests in the Company by Mr. Kokorich, his wife, and entities that they control in response to concerns of the U.S. Department of Defense regarding the Company’s foreign ownership and control. On June 8, 2021, the U.S. Departments of Defense and the Treasury, on behalf of CFIUS, Mr. Kokorich, on behalf of himself and Nortrone Finance S.A. (an entity controlled by Mr. Kokorich), Lev Khasis and Olga Khasis, each in their respective individual capacities and on behalf of Brainyspace LLC (an entity controlled by Olga Khasis) entered into the NSA. In accordance with the NSA and pursuant to stock repurchase agreements entered into with the Company, effective as of June 8, 2021, each of Mr. Kokorich, Nortrone Finance S.A. and Brainyspace LLC (collectively “the Co-Founders”) agreed to sell 100% of their respective equity interests in the Company on June 30, 2021. The Company paid an aggregate of $40 million to the Co-Founders following the Business Combination, and an additional payment of an aggregate of $10 million was payable within 10 business days after cumulative business combination or capital raising transactions (whether in the form of debt or equity) resulted in cash proceeds to the Company of no less than $250 million. On February 27, 2023 the Company raised aggregate gross proceeds of $10.0 million through the sale of securities (see Note 9 for additional information), which together with the Business Combination and other capital raising activities triggered the $10.0 million liability to the Co-Founders in accordance with the terms of the stock repurchase agreements. The amount had previously been recorded as an estimated liability with a corresponding offset to additional paid-in capital within the consolidated statements of stockholders’ equity as of December 31, 2022. CFIUS terminated the NSA in January 2024 at the request of the Company, and the Company is no longer subject to the provisions of the NSA. The Company incurred legal expenses related to these matters of approximately $0.4 million and $1.7 million for the years ended December 31, 2023 and 2022, respectively, and expects to continue to incur legal expenses in the future. Shareholder Section 220 Litigation On June 16, 2022, Plaintiff and the Company’s shareholder James Burk filed a verified complaint against the Company in the Delaware Court of Chancery, Case. No. 2022-0519, to inspect the books and records of the Company pursuant to Section 220 of the Delaware General Corporation Law. Plaintiff seeks production of books and records relating to the management of the Company and its disclosures to potential investors in connection with the Business Combination. On March 14, 2023, the Court granted the parties stipulation of dismissal with prejudice, and the matter was closed. The Company from time to time responds to books and records requests properly submitted pursuant to applicable Delaware law. Shareholder Derivative Litigation On June 20, 2022, a shareholder derivative action was filed by Brian Lindsey, on behalf of the Company, in the U.S. District Court for the Central District of California, Case No. 2:22-cv-04212, against the Company (as a nominal defendant), SRAC, Brian Kabot, Juan Manuel Quiroga, James Norris, James Hofmockel, Mikhail Kokorich, Dawn Harms, Fred Kennedy, Chris Hadfield, Mitchel B. Kugler, Victorino Mercado, Kimberly A. Reed, Linda J. Reiners, and John C. Rood. This derivative action alleges the same core allegations as stated in the securities class action litigation. Defendants dispute the allegations as stated in this derivative action. On September 27, 2022, Plaintiff filed his Notice of Voluntary Dismissal without Prejudice seeking to dismiss the case. Because Plaintiff’s dismissal of this derivative action was voluntary and without prejudice, this plaintiff and/or other shareholders may seek to re-file the claims asserted in this matter at a later date. As noted below, Brian Lindsey re-filed a shareholder derivative action in Delaware Chancery Court on June 30, 2023. On January 25, 2023, a shareholder derivative action was filed by Melissa Hanna, on behalf of the Company, in the U.S. District Court for the Northern District of California, Case No. 5:23-cv-00374, against the Company (as a nominal defendant), SRAC, Brian Kabot, Juan Manuel Quiroga, James Norris, James Hofmockel, Mikhail Kokorich, Dawn Harms, Fred Kennedy, Chris Hadfield, Mitchel B. Kugler, Victorino Mercado, Kimberly A. Reed, Linda J. Reiners, and John C. Rood (the “Derivative Action II”). The Derivative Action II alleges the same core allegations as stated in the Securities Class Actions, and also claims that the Company ignored and/or refused a prior demand made by Ms. Hanna on the Company’s Board of Directors. The Company intends to vigorously defend the litigation. On April 25, 2023, a shareholder derivative action was filed by Justin Rivlin, purportedly on behalf of the Company, in the U.S. District Court for the District of California, Case No. 2:23-cv-03120, against the Company (as a nominal defendant), Brian Kabot, James Norris, Marc Lehmann, James Hofmockel, and Ann Kono. The Rivlin derivative action alleges the same core allegations as stated in the Securities Class Actions. The Company has filed a motion to dismiss the complaint on the grounds that the claims are time-barred and that the plaintiff was not excused from making a demand on the Company before filing the lawsuit. The Company intends to vigorously defend the litigation. On August 4, 2023, the plaintiff in the Rivlin action responded to the Company’s motion to dismiss by filing an amended complaint adding new claims and new defendants, including existing Board members Chris Hadfield, Mitchel B. Kugler, Kimberly A. Reed, Linda J. Reiners and John C. Rood. On June 30, 2023, a shareholder derivative action was filed by Brian Lindsey, purportedly on behalf of the Company in the Court of Chancery for the State of Delaware (Case No. 2023-0674), against the Company (as a nominal defendant), Juan Manuel Quiroga, James Norris, James Hofmockel, Stable Road Acquisition Corp., SRC-NI Holdings, LLC, Mikhail Kokorich, Brian Kabot, Dawn Harms, Fred Kennedy, Chris Hadfield, Mitchel B. Kugler, Victorino Mercado, Kimberly A. Reed, Linda J. Reiners and John C. Rood. The Lindsey derivative action alleges the same core allegations as stated in the Securities Class Actions. The Company intends to vigorously defend the litigation. The Company and other defendants held a joint mediation on October 25, 2023 with the plaintiffs in the Hanna, Rivlin and Lindsey derivative actions. The mediation did not result in a settlement at that time, but the parties are continuing to discuss possible settlement under the supervision of the mediator. If the cases do not settle, the Company intends to defend the action vigorously. SAFE Note Litigation On July 20, 2022, The Larian Living Trust ("TLLT") filed an action against the Company in New Castle County Superior Court, Delaware, in the Complex Commercial Litigation Division, Case No. N22C-07-133 EMD CCLD. TLLT pleads claims for fraudulent inducement and breach of contract arising from two investment contracts pursuant to which TLLT alleges it invested $4.0 million in the Company. TLLT alleges that a "liquidity event" occurred when the Company closed the Business Combination, such that it was entitled to the greater of its $4.0 million investment or its “Conversion Amount” of the Company’s shares, which was a total of 14,500 shares of the Company’s stock. TLLT further alleges that the Company refused to provide it the conversion amount of shares until April 2022, at which point the value of its shares had dropped significantly from their peak value in August of 2021, in excess of $7.6 million. TLLT seeks damages in excess of $7.6 million, in addition to interests and its attorney's fees and costs. On March 16, 2023, the Company’s motion to dismiss TLLT’s claims was denied and the parties will move forward with discovery. On July 13, 2023, the Company filed a motion for partial summary judgment. The hearing on the Company’s motion for partial summary judgment was set for November 8, 2023, TLLT filed an Answering Brief on September 15, 2023, and the Company filed a Reply Brief on October 16, 2023. On January 31, 2024, the Superior Court denied the Company’s motion for partial summary judgment. The Company disputes the allegations in the complaint and intends to vigorously defend the litigation. Founder Litigation On June 8, 2021, former co-founders and shareholders of the Company, Mikhail Kokorich and Lev Khasis signed the NSA alongside stock repurchase agreements, whereby they agreed to divest their interests in the Company in exchange for a cash payments and other considerations. As part of the NSA and stock repurchase agreements, Messrs. Kokorich and Khasis agreed to a broad waiver and release of all claims (broadly defined) against the Company. The Company has maintained that this release is effective as to various advancement and indemnification claims either individual may have against the Company. Both Messrs. Kokorich and Khasis have, through counsel, disagreed with the Company’s position. For example, Mr. Kokorich is named as a defendant in the securities class action pending against the Company and other defendants, although he has not been served nor appeared in those matters. In addition, Mr. Kokorich is the sole defendant in a civil litigation action filed against him by the Securities and Exchange Commission, which remains pending in the US District Court for the District of Columbia, Case No. 1:21-cv-01869. Mr. Kokorich has demanded indemnification and advancement from the Company for his fees and costs incurred in these actions, which claims are disputed by the Company. The Company continues to maintain that Mr. Kokorich’s release in the NSA and stock repurchase agreements is effective as to his claims for advancement and indemnification in these litigation matters. On August 16, 2022, Mr. Kokorich filed a verified complaint against the Company in the Delaware Court of Chancery (Case. No. 2022-0722) seeking indemnification and advancement from the Company. Following the Company filing a motion to dismiss this action, on November 14, 2022, Mr. Kokorich filed an amended complaint. Additional motions to dismiss and replies were filed and considered at a hearing on February 2, 2023. The Delaware Court of Chancery granted the Company’s motion to dismiss the Kokorich indemnification claim action on May 15, 2023.On June 13, 2023, Kokorich filed a notice of appeal. On July 28, 2023, Kokorich filed Appellant’s Brief. The Company filed Appellee’s Answering Brief on August 28, 2023, and Kokorich filed a Reply Brief on September 15, 2023. The oral argument on Kokorich’s appeal was scheduled for November 15, 2023. On November 30, 2023, the Delaware Supreme Court affirmed the judgement of the Delaware Court of Chancery. On March 24, 2023, Mr. Khasis filed a verified complaint against the Company in the Delaware Court of Chancery (Case. No. 2023-0361) seeking indemnification and advancement of expenses from the Company. On April 17, 2023, the Company filed a motion to dismiss. On May 16, 2023. Mr. Khasis filed an amended complaint. On May 23, 2023, Momentus filed a motion to dismiss the amended complaint. Separately, Khasis has requested an expedited trial in his claim for advancement of fees. On June 23, 2023, the Court of Chancery ordered that Khasis indemnification litigation will not be stayed pending the appeal of the Kokorich claim. Moreover, the Court of Chancery further ordered the parties to prepare a scheduling order to the Court which includes all relevant deadlines to argue the Company’s motion to dismiss and Khasis’ expedited motion for advancement concurrently. The parties are currently negotiating concerning an acceptable schedule. On October 17, 2023, the parties reached an agreement to stay the proceeding until January 1, 2024. On October 18, 2023, the Company paid Mr. Khasis $0.1 million related to Mr. Khasis’ legal expenses. The Company disputes the allegations in the complaint and intends to vigorously defend the litigation. Delaware Class Actions On November 10, 2022, purported stockholders filed a putative class action complaint against Brian Kabot, James Hofmockel, Ann Kono, Marc Lehmann, James Norris, Juan Manuel Quiroga, SRC-NI Holdings, LLC, Edward K. Freedman, Mikhail Kokorich, Dawn Harms, Fred Kennedy, and John C. Rood in the Court of Chancery of the State of Delaware, in a case captioned Shirley, et al. v. Kabot et al., 2022-1023-PAF (the “Shirley Action”). The complaint alleges that the defendants made certain material misrepresentations, and omitted certain material information, in their public statements and disclosures regarding the Proposed Transaction, in violation of the securities laws, and seeks damages on behalf of a putative class of stockholders who purchased SRAC stock on or before August 9, 2021. On March 16, 2023, purported stockholders of the Company filed a putative class action complaint against certain current and former directors and officers of the Company in the Delaware Court of Chancery, in a case captioned Lora v. Kabot, et al., Case No. 2023-0322 (the “Lora Action”). Like the Shirley complaint, the complaint alleges that the defendants made certain material misrepresentations, and omitted certain material information, in their public statements and disclosures regarding the Business Combination in violation of the securities laws, and seeks damages on behalf of a putative class of stockholders who purchased SRAC stock on or before August 9, 2021. On March 17, 2023, purported stockholders of the Company filed a putative class action complaint against certain current and former directors and officers of the Company in the Delaware Court of Chancery, in a case captioned Burk v. Kabot, et al., Case No. 2023-0334 (the “Burk Action”). Like the Lora and Shirley complaints, the Burk complaint alleges that the defendants made certain material misrepresentations, and omitted certain material information, in their public statements and disclosures regarding the Business Combination in violation of the securities laws, and seeks damages on behalf of a putative class of stockholders who purchased SRAC stock on or before August 9, 2021. On May 26, 2023, plaintiffs filed a stipulation and proposed order for consolidation and appointment of co-lead plaintiffs and co-lead plaintiffs’ counsel designating the complaint filed in the Lora Action as the operative complaint.On June 30, 2023, the defendants each filed a motion to dismiss the complaint. On October 26, 2023, plaintiffs filed their answering briefs in opposition to the motions to dismiss, and the defendants’ reply briefs are due to be filed on or before December 14, 2023, and a hearing on the motions to dismiss was held for February 1, 2024. The Shirley Action, the Lora Action, and the Burk Action have been consolidated under the caption, In re Momentus, Inc. Stockholders Litigation, C.A. No. 2022-1023-PAF (Del Ch. Nov. 10, 2022). These putative class actions do not name the Company as a defendant. Regardless, the SRAC directors and officers, together with current and former directors and officers of the Company, have demanded indemnification and advancement from the Company, under the terms of the merger agreement and the exhibits thereto, the Delaware corporate code, the Company’s bylaws, and their individual indemnification agreements. The Company may be liable for the fees and costs incurred by the defendants, and has an obligation to advance such fees during the pendency of the litigation. The Company understands that the defendants dispute the allegations in the complaint and intend to vigorously defend against any such litigation. Threatened Claims On October 23, 2023, Stephen J. Purcell, on behalf of the law firm Purcell & Lefkowitz LLP, threatened to file a legal proceeding to receive attorney’s fees in the amount of $80,000 related to a stockholder litigation demand letter submitted to Momentus, dated July 20, 2021 on behalf of Joel Zalvin, a purported stockholder of Momentus. The stockholder litigation demand letter asserted that the vote to increase the number of shares of Class A common stock of Momentus at the special meeting of stockholders on August 11, 2021 was conducted in violation of Delaware law. On March 14, 2023, the Delaware Court of Chancery granted the Company’s request pursuant to 8 Del. C. §205, or Section 205 of the Delaware General Corporation Law (the “Petition”) in order to validate and declare effective the Second Amended and Restated Certificate of Incorporation of the Company and validate and declare effective the shares of the Company’s Class A common stock issued in reliance on such provisions of the Second Amended and Restated Certificate of Incorporation of the Company as of the date of the original issuance of such shares. Further on March 14, 2023, the Court of Chancery entered an order under 8 Del. C. §205 (i) declaring the Second Amended and Restated Certificate of Incorporation of the Company, including the filing and effectiveness thereof, as validated and effective retroactive to the date of its filing with the Office of the Secretary of State of the State of Delaware on August 12, 2021, and (ii) ordering that the Company’s Class A common stock (and the issuance of the Class A common stock) described in the Petition and any other securities issued in reliance of the validity of the Second Amended and Restated Certificate of Incorporation of the Company are validated and declared effective, each as of the original issuance dates. Momentus did not take action in response to the July 20, 2021 demand letter, but rather filed the Petition over one year later, following a decision by the Delaware Chancery Court that created uncertainty as to the validity of the Company’s Second Amended and Restated Certificate of Incorporation. Accordingly, Momentus believes that the threatened claim is without merit and intends to vigorously defend any such claim if brought. Prior to the close of the Business Combination, Alex Ciccotelli, represented by Rigrodsky Law, sent SRAC a disclosure demand letter dated November 9, 2020, and Jeffrey Justice II, represented by Grabar Law Office, sent SRAC a disclosure demand letter dated August 3, 2021. Mr. Ciccotelli then filed a civil action against SRAC. After receiving various shareholder disclosure demands, SRAC voluntarily issued certain pre-closing supplemental disclosures, without admission, as stated in its August 5, 2021 Form 8-K filing. The Ciccotelli action was thereafter dismissed as moot. On March 20, 2023, Rigrodsky Law threatened to file a fee petition seeking an award of fees and expenses if the Company does not agree to pay a mootness fee, and more recently, in October 2023, reiterated the demand on behalf of Messrs. Ciccotelli and Justice for payment of mootness fees. The Company maintains that, while certain amendments were made by SRAC to pre-closing disclosures, none of the disclosures made was material and the Company disputes that the claims for fees have merit. Other Litigation and Related Matters These and other litigation matters may be time-consuming, divert management’s attention and resources, cause the Company to incur significant defense and settlement costs or liability, even if we believe the claims asserted against us are without merit. We intend to vigorously defend against all such claims. Because of the potential risks, expenses and uncertainties of litigation, as well as claims for indemnity from various of the parties concerned, we may from time to time, settle disputes, even where we believe that we have meritorious claims or defenses. Because litigation is inherently unpredictable, further compounded by various claims for indemnity which may or may not be fully insured, we cannot assure that the results of these actions, either individually or in the aggregate, will not have a material adverse effect on our consolidated operating results and financial condition. From time to time, the Company may be a party to litigation and subject to claims incident to the ordinary course of business or in connection with the matters discussed above. Although the results of litigation and claims cannot be predicted with certainty, the Company currently believes that the final outcome of these matters will not have a material adverse effect on its business. Regardless of the outcome, litigation can have an adverse impact on the Company because of judgment, defense and settlement costs, diversion of management resources and other factors. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC Sub-Topic 450-20. Legal fees are expensed as incurred. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Note 13. Income Taxes The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate for the years ended December 31, 2023 and 2022: (in thousands) December 31, 2023 December 31, 2022 Tax provision (benefit) at U.S. statutory rate $ (14,473) 21.0 % $ (20,042) 21.0 % State income taxes, net of federal benefit $ (6,694) 9.7 % $ 11,113 (11.6) % Non-deductible expenses 261 (0.4) % (60) 0.1 % Change in value of equity instruments (118) 0.2 % (1,089) 1.1 % Deferred adjustments (56) 0.1 % (143) 0.2 % Other (172) 0.3 % — — % Research and development credits (274) 0.4 % (1,085) 1.1 % IRC Sec. 174 217 (0.3) % — — % Uncertain tax positions 69 (0.1) % 276 (0.3) % Change in valuation allowance 21,240 (30.8) % 11,030 (11.6) % $ — — % $ — — % Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table presents the significant components of the Company’s deferred tax assets and liabilities as of December 31, 2023 and 2022: (in thousands) December 31, December 31, Deferred tax assets: Net operating loss carryforwards $ 37,037 $ 16,562 Start-up and Organization Costs 16,913 16,965 Capitalized research and development credits 10,943 17,922 Intangibles 6,703 22 Stock-based compensation 4,972 3,072 Research and development credits 4,842 4,595 Operating lease obligations 1,375 1,534 Accrued expenses and reserves 621 1,710 Property and equipment 233 173 Other 1 1 Total deferred tax assets before valuation allowance 83,640 62,556 Valuation allowance (82,440) (61,200) Total deferred tax assets $ 1,200 $ 1,356 Deferred Tax Liabilities: Operating lease right-of-use assets $ (1,200) $ (1,356) Total deferred tax liabilities $ (1,200) $ (1,356) Net deferred tax assets $ — $ — In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. As a result of a history of taxable losses and uncertainties as to future profitability, the Company recorded a full valuation allowance against its deferred tax assets. The valuation allowance for the year ended December 31, 2023 was $82.4 million. As of December 31, 2023, the Company has federal and state net operating loss (“NOL”) carryforwards of $157.3 million and $55.9 million, respectively. As of December 31, 2022, the Company had federal and state NOL carryforwards of $77.5 million and $46.4 million, respectively. While the federal NOLs can be carried forward indefinitely, California NOLs begin to expire in the year ending December 31, 2038. As of December 31, 2023, the Company had federal and California research and development credit carryforwards of $4.0 million and $3.1 million, respectively. As of December 31, 2022, the Company had federal and California research and development credit carryforwards of $3.7 million and $3.0 million, respectively. The federal research and development credit will begin to expire in the year ending December 31, 2039, and the California research and development credit has no expiration. ASC Topic 740-10 requires companies to determine whether it is “more likely than not” that a tax position will be sustained upon examination by the appropriate taxing authorities before any tax benefit can be recorded in the consolidated financial statements. It also provides guidance on the recognition, measurement, classification and interest and penalties related to uncertain tax positions. The following table summarizes the activity related to the Company’s gross unrecognized tax benefits: (in thousands) Gross unrecognized tax benefits Balance as of December 31, 2022 $ 1,712 Increases related to prior tax positions (29) Increases related to current tax positions 96 Balance as of December 31, 2023 $ 1,779 The Company’s policy is to record estimated interest and penalties related to the underpayment of income taxes or unrecognized tax benefits as a component of its income tax provision. The Company has not recorded any interest or penalties related to unrecognized tax benefits through December 31, 2023. In the normal course of business, the Company is subject to examination by federal and state jurisdictions where applicable based on the statue of limitations that apply in each jurisdiction. The tax return years 2018 through 2022 remain open to examination. The Company is not currently under audit by the taxing jurisdictions to which the Company is subject. The Company performed IRC Section 382 study for year-ended December 31, 2021. In its study, the Company identified two changes to the ownership, resulting in the limitation of the net operating loses. The first change of ownership occurred on November 1, 2018 and the second change of ownership occurred on June 8, 2021. In it's study of section 382, the Company identified that there were limitations to NOLs, however, none of the NOLs will expire utilized. An IRC Section 382 refresh study for year-ended December 31, 2023 has not been performed. The Company does not anticipate any material change in its unrecognized tax benefits in the next twelve months. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2023 | |
Subsequent Events [Abstract] | |
Subsequent Events | Note 14. Subsequent Events January 2024 Registered Direct Securities Sale On January 12, 2024, the Company entered into an agreement to sell 900,000 shares of Class A common stock at a purchase price of $1.09 per share, resulting in total gross proceeds of approximately $4.0 million before deducting placement agent commissions and other estimated offering expenses (the “January 2024 Offering”). As part of the January 2024 Offering, the Company issued to the investor (i) 2,787,000 pre-funded warrants (the “January 2024 Pre-Funded Warrants”) which were exercised immediately and (ii) 3,687,000 warrants with a strike price of $0.96 (the “January 2024 Warrants”). The January 2024 Warrants will be exercisable immediately after issuance and will expire five years from the date of issuance. The offering closed on January 17, 2024. In connection with the January 2024 Offering, the Company also agreed to amend each of the November Warrants to purchase up to an aggregate of 5,808,538 shares of Class A common stock at an exercise price of $3.86 per share. Prior to amendment, the November Warrants had a termination date of November 9, 2028. Upon amendment, each of the November Warrants will have a reduced exercise price of $0.96 per share and a termination date of January 17, 2029. National Security Agreement Termination On January 31, 2024, the Company was informed by the Department of the Treasury that the Company had completed all specified requirements under the NSA pursuant to which, among other things, the Company was required to comply with various requirements and compliance measures to protect national security. As a result, the NSA has been terminated in its entirety. Experior Lawsuit On February 16, 2024, Experior Laboratories, Inc. (“Experior”) filed a breach of contract action against the Company seeking monetary damages in the amount of $143,256.00, plus prejudgment interest, costs, and attorney’s fees for the alleged breach of written agreements between Experior and the Company regarding the provision of testing services to the Company by Experior. Experior Laboratories, Inc. v. Momentus Inc., et al., Superior Court of California, Count of Ventura, Case No. 2024CUBC020886. By agreement with Experior, the filing date for the Company’s response to the complaint is no earlier than June 10, 2024, and the parties have been engaged in settlement discussions. The Company disputes the amount of the damages claimed, though it is probable that the Company is liable for some of the amount sought by Experior. If necessary, the Company intends to assert a counterclaim for damages or a claim for a set-off arising from injuries suffered by the Company as a result of Experior’s actions in providing the contract services. Assignment of SpaceX RSA to D-Orbit On February 19, 2024, the Company assigned a SpaceX Rideshare Service Agreement (the “RSA”) to D-Orbit SpA (“D-Orbit”) in exchange for $1.3 million, representing the amount the Company had paid to date to SpaceX under the RSA. March 2024 Registered Direct Securities Sale On March 4, 2024, the Company entered into an agreement to sell 1,320,000 shares of Class A common stock, at a purchase price of $0.87 per share, resulting in total gross proceeds of approximately $4.0 million before deducting placement agent commissions and other estimated offering expenses (the “March 2024 Offering”). As part of the March 2024 Offering, the Company issued to the investor (i) 3,304,280 pre-funded warrants which were exercised immediately (the “March 2024 Pre-Funded Warrants”) and (ii) 4,624,280 warrants with a strike price of $0.74 (the “March 2024 Warrants”). The March 2024 Warrants will be exercisable immediately after issuance and will expire five years from the date of issuance. The offering closed on March 7, 2024. In connection with the January Offering, the Company also agreed to amend each of the November Warrants and January 2024 Warrants to purchase up to an aggregate of 5,808,538 and 3,687,000 shares of Class A common stock, respectively, at an exercise price of $0.96 per share. Prior to amendment, the November Warrants and January 2024 Warrants had a termination date of January 17, 2029. Upon amendment, each of the November Warrants and January 2024 Warrants will have a reduced exercise price of $0.74 per share and a termination date of March 7, 2029. Change in Chief Financial Officer On March 28, 2024, Eric Williams, the Chief Financial Officer of the Company, tendered his resignation effective March 31, 2024. On March 28, 2024, the Board of Directors appointed Lon Ensler as the Interim Chief Financial Officer and principal accounting officer of the Company, effective as of April 1, 2024. |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Pay vs Performance Disclosure | ||
Net loss | $ (68,920) | $ (95,444) |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Dec. 31, 2023 | |
Trading Arrangements, by Individual | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Principles of Consolidation | The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation. |
Reclassification, Change in Presentation and Prior Year Omitted Disclosures | Certain prior period amounts in the consolidated financial statements and accompanying notes have been reclassified to conform to the current period’s presentation as follows. Disclosures including the disaggregation of revenue by type (refer to “disaggregation of revenue by type” in this Note), disclosure in segment reporting regarding the long-lived assets by geographic location (refer to “segment reporting” in this Note), the disclosure of Preferred Stock and Class B common stock on the consolidated balance sheet and the disclosure of Class B common stock in Note 9 were omitted from our prior year financials for the year ended December 31, 2022. The disclosures have been included for the year ended December 31, 2023 and include the comparative period for the year ended December 31, 2022. Additionally, there was an immaterial number change related to the disclosure of gross unrecognized tax benefits (refer to “Gross unrecognized tax benefits” in Note 13) for the year-ended December 31, 2022. The Company also adjusted the 2022 federal and state net operating loss (“NOL’s”) carryforwards as the result of the 2023 return to provision true-up that was recorded in relation to the state apportionments (refer to disclosures in Note 13). These adjustments had no impact on the consolidated balance sheets, statements of operations and comprehensive loss, or cash flows as there was no change in the amounts recorded. The Company has determined that these adjustments were immaterial both individually and in aggregate. |
Use of Estimates | The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other factors it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Accordingly, actual results could differ from those estimates. Significant estimates inherent in the preparation of the consolidated financial statements include, but are not limited to, the timing of revenue recognition, accounting for useful lives of property, machinery and equipment, net, intangible assets, net, accrued liabilities, leases, income taxes including deferred tax assets and liabilities, impairment valuation, stock-based compensation, warrant liabilities, and litigation contingencies. |
Emerging Growth Company Status | Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can choose not to take advantage of the extended transition period and comply with the requirements that apply to non-emerging growth companies, and any such election to not take advantage of the extended transition period is irrevocable. The Company is an “emerging growth company” as defined in Section 2(a) of the Securities Act and has elected to take advantage of the benefits of the extended transition period for new or revised financial accounting standards. The Company will remain an emerging growth company until the earliest of (i) the last day of the fiscal year in which the market value of Class A common stock that is held by non-affiliates exceeds $700 million as of the end of that year’s second fiscal quarter, (ii) the last day of the fiscal year in which the Company after the consummation of the Business Combination has total annual gross revenue of $1.07 billion or more during such fiscal year (as indexed for inflation), (iii) the date on which the Company has issued more than $1 billion in non-convertible debt in the prior three-year period or (iv) December 31, 2024. The Company expects to continue to take advantage of the benefits of the extended transition period, although it may decide to early adopt such new or revised accounting standards to the extent permitted by such standards. This may make it difficult or impossible to compare the Company’s financial results with the financial results of another public company that is either not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition period exemptions because of the potential differences in accounting standards used. |
Cash and Cash Equivalents and Restricted Cash | Cash and cash equivalents consist of cash on hand, cash in bank with no restrictions, as well as highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities of three months or less when initially purchased. The Company places its cash in the bank, which may at times be in excess of the Federal Deposit Insurance Corporation insurance limits of $250,000 per depositor, with high credit quality financial institutions and attempts to limit the amount of credit exposure with any one institution. |
Deferred Fulfillment and Prepaid Launch Costs | The Company prepays for certain launch costs to third-party providers that will carry the transport vehicle to orbit. Prepaid costs allocated to the delivery of a customers’ payload are classified as deferred fulfillment costs and recognized as cost of revenue upon delivery of the customers’ payload. Prepaid costs allocated to our payload are classified as prepaid launch costs and are amortized to cost of sales and research and development expense upon the release of our payload. The allocation is determined based on the distribution between customer and our payload weight on each launch. |
Property, Machinery and Equipment | Property, machinery and equipment are stated at cost less accumulated depreciation. Depreciation is generally recorded using the straight-line method over the estimated useful lives of the respective assets. The estimated useful lives of fixed assets by asset category are described below: Fixed Assets Estimated Useful Life Computer equipment Three years Furniture and fixtures Five years Leasehold improvements Lesser of estimated useful life or remaining lease term (one year to seven years) Machinery and equipment Seven years Costs of maintenance or repairs that do not extend the lives of the respective assets are charged to expenses as incurred. |
Intangible Assets | Intangible assets, which consist of patents, are considered long-lived assets and are reported at cost less accumulated amortization and accumulated impairment loss, if any. Amortization is recognized on a straight-line basis over 10 years for patents, which is the estimated useful lives of the intangible assets. In accordance with ASC Topic 350-40, Intangibles , the Company presents capitalized implementation costs for cloud computing arrangements within prepaid and other current assets, and other non-current assets to properly present the capitalized costs with their related subscription fees. |
Deferred Offering Costs | Offering costs consist of legal, accounting, underwriting fees and other costs incurred that are directly related to fundraising activities. During the years ended December 31, 2023 and 2022, deferred offering costs were attributable to the Company’s S-3 Universal Shelf registration (the “Form S-3”), the at-the-market offering program, and securities purchase agreements entered into during such periods. These costs will be netted with the proceeds proportional to the at-the-market program fundraising and any future fundraising under the "Form S-3". If the Company terminates the Form S-3 or the at-the-market program, or there is a significant delay, all of the deferred offering costs attributed to the Form S-3 or the at-the-market offering program will be immediately written off. |
Loss Contingencies | The Company estimates loss contingencies in accordance with ASC Sub-Topic 450-20, Loss Contingencies |
Revenue Recognition | The Company enters into short-term contracts for ‘last-mile’ satellite and cargo delivery (transportation service), payload hosting and in-orbit servicing options with customers that are primarily in the aerospace industry. For its transportation service arrangements, the Company has a single performance obligation of delivering the customers’ payload to its designated orbit and recognizes revenue (along with any other fees that have been paid) at a point in time, upon satisfaction of this performance obligation. Additionally, for its in-orbit service arrangements, the Company provides a multitude of services consistently throughout the mission to its customers and also has services available on a ‘stand ready’ basis as needed until the mission reaches its conclusion. The Company recognizes revenue for these in-orbit services ratably over time on a straight-line basis. The Company also enters into contracts to perform analysis and provide engineering services to U.S. Government organizations. The Company accounts for customer contracts in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), which includes the following five-step model: • Identification of the contract, or contracts, with a customer. • Identification of the performance obligations in the contract. • Determination of the transaction price. • Allocation of the transaction price to the performance obligations in the contract. • Recognition of revenue when, or as, the Company satisfies a performance obligation. The Company estimates variable consideration at the most likely amount, which is included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. While the Company’s standard contracts do not contain refund or recourse provisions that enable its customers to recover any non-refundable fees that have been paid, the Company may issue full or partial refunds, or concessions on future services to customers on a case-by-case basis as necessary to preserve and foster future business relationships and customer goodwill. Contracts to provide engineering services to U.S. Government organizations generally have set payments tied to each milestone. When a milestone is achieved, the Company submits the completed service for |
Fair Value Measurement | The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. A three-tiered hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires that the Company use observable market data, when available, and minimize the use of unobservable inputs when determining fair value: • Level 1, observable inputs such as quoted prices in active markets; • Level 2, inputs other than the quoted prices in active markets that are observable either directly or indirectly; and • Level 3, unobservable inputs in which there is little or no market data, which requires that the Company develop its own assumptions. The fair values of cash and cash equivalents, accounts payable, and certain prepaid and other current assets and accrued expenses approximate carrying values due to the short-term maturities of these instruments which fall with Level 1 of the fair value hierarchy. The carrying value of certain other non-current assets and liabilities approximates fair value. The Company had no Level 2 instruments for the years ended December 31, 2023 and 2022. Certain of the Company’s warrants are recorded as a derivative liability pursuant to ASC Topic 815, Derivatives and Hedging (“ASC Topic 815”), and are classified within Level 3 of the fair value hierarchy as the Company is using the Black Scholes Option Pricing model. The primary significant unobservable input used in the valuation of the warrants is expected stock price volatility. Expected stock price volatility is based on the actual historical volatility of a group of comparable publicly traded companies observed over a historical period equal to the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the warrants. The expected term was based on the maturity of the warrants, which is 5 years. The dividend yield percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. Upon conversion of the Legacy Momentus private warrants immediately prior to the business combination, the key valuation input was the closing price of Company’s Class A common stock on the Closing, as the expected term and volatility were immaterial to the pricing model. |
Warrant Liability | The Company’s private warrants and stock purchase warrants are recorded as derivative liabilities pursuant to ASC Topic 815 and are classified within Level 3 of the fair value hierarchy as the Company is using the Black Scholes Option Pricing model to calculate fair value. See Note 9 for additional information. Significant unobservable inputs, prior to the Company’s stock being publicly listed, included stock price, volatility and expected term. At the end of each reporting period, changes in fair value during the period are recognized as components of other income within the consolidated statements of operations. The Company will continue to adjust the warrant liability for changes in fair value until the earlier of (i) the exercise or expiration of the warrants or (ii) the redemption of the warrants, at which time the warrants will be reclassified to additional paid-in capital within the consolidated statements of stockholders’ equity. The warrants issued by Momentus Inc. prior to the Business Combination were exercised in connection with the Business Combination and as a result, the Company performed a fair value measurement of those warrants on the Closing and recorded the change in the instruments’ fair values prior to converting them to equity. The warrants assumed by the Company as a result of the Business Combination remain outstanding. Public and Private Warrants Prior to the Business Combination, SRAC issued 225,450 private placement warrants (“Private Warrants”) and 172,500 public warrants (“Public Warrants” and, together with the “Private Warrants”, “Public and Private Warrants”). Each whole warrant entitles the holder to purchase one share of the Company’s Class A common stock at a price of $575.00 per share, subject to adjustments and will expire five years after the Business Combination or earlier upon redemption or liquidation. The Private Warrants do not meet the derivative scope exception and are accounted for as derivative liabilities. Specifically, the Private Warrants contain provisions that cause the settlement amounts to be dependent upon the characteristics of the holder of the warrant which is not an input into the pricing of a fixed-for-fixed option on equity shares. Therefore, the Private Warrants are not considered indexed to the Company’s stock and should be classified as a liability. Since the Private Warrants meet the definition of a derivative, the Company recorded the Private Warrants as liabilities on the consolidated balance sheet at fair value upon the Closing, with subsequent changes in the fair value recognized in the consolidated statements of operations at each reporting date. The fair value of the Private Warrants was measured using the Black-Scholes option-pricing model at each measurement date. In addition, the Public Warrants are accounted for as equity classified by the Company. On consummation of the Business Combination, the Company recorded equity related to the Public Warrants of $20.2 million, with an offsetting entry to additional paid-in capital. Similarly, on the consummation of the Business Combination, the Company recorded a liability related to the Private Warrants of $31.2 million, with an offsetting entry to additional paid-in capital. The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC Topic 815, at the initial recognition. Other than the Public and Private Warrants noted above, the Company also had other warrants issued and outstanding which were recognized as derivative liabilities in accordance with ASC Topic 815 until they were fully exercised. Accordingly, the Company recognized the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period until exercised. The fair value of the warrant liabilities issued were initially measured using the Black-Scholes model and were subsequently remeasured at each reporting period with changes recorded as a component of other income in the Company’s consolidated statements of operations. Derivative warrant liabilities are classified as non-current as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. See Note 9 for additional information. |
Equity Classified Warrants | Subsequent to the Business Combination, the Company has issued warrants in conjunction with various securities purchase agreements (See Note 9 for additional information). The warrants are freestanding equity-linked instruments that meet the indexation and equity classification criteria of ASC Sub-Topic 815-40. The grant-date fair value of these warrants is recorded in additional paid-in capital on the consolidated balance sheets. The fair value of the warrants are measured using the Black-Scholes option-pricing model on the grant date. |
Modification of Equity Classified Warrants | A change in the terms or conditions of a warrant is accounted for as a modification. For a warrant modification accounted for under ASC Topic 815, the effect of a modification shall be measured as the difference between the fair value of the modified warrant and the fair value of the original warrant immediately before its terms are modified, with each measured on the modification date. The accounting for incremental fair value of the modified warrants over the original warrants is based on the specific facts and circumstances related to the modification. When a modification is directly attributable to an equity offering, the incremental change in fair value of the warrants is accounted for as an equity issuance cost. When a modification is directly attributable to a debt offering, the incremental change in fair value of the warrants is accounted for as a debt discount or debt issuance cost. For all other modifications, the incremental change in fair value is recognized as a deemed dividend. |
Basic and Diluted Loss Per Share | Net loss per share is provided in accordance with ASC Sub-Topic 260-10, Earnings per Share |
Impairment of Long-lived Assets | The Company evaluates the carrying value of long-lived assets, which includes intangible assets, on an annual basis, or more frequently whenever circumstances indicate a long-lived asset may be impaired. When indicators of impairment exist, the Company estimates future undiscounted cash flows attributable to such assets. In the event |
Stock-based Compensation | The Company has a stock incentive plan under which equity awards are granted to employees, directors, and consultants. All stock-based payments are recognized in the consolidated financial statements based on their respective grant date fair values. Restricted stock unit fair value is based on our closing stock price on the day of the grant. Stock option fair value is determined using the Black Scholes Merton Option Pricing model. The model requires management to make a number of assumptions, including expected volatility of the Company’s stock, expected life of the option, risk-free interest rate, and expected dividends. Employee Stock Purchase Plan (“ESPP”) compensation fair value is also determined using the Black Scholes Merton Option Pricing model, using a six-month expected term to conform with the six month ESPP offering period. The fair value of equity awards is expensed over the related service period which is typically the vesting period, and expense is only recognized for awards that are expected to vest. The Company accounts for forfeitures as they occur. |
401(k) Plan | The Company has a 401(k) plan that it offers to its full-time employees. The Company did not contribute to the plan for the years ended December 31, 2023 and 2022. |
Research and Development Costs | Research and development costs are expensed as incurred. Research and development costs include activities to develop existing and future technologies for the Company’s vehicles. Research and development activities include basic research, applied research, design, development, and related test program activities. Costs incurred for developing our vehicles primarily include equipment, material, and labor hours (both internal and subcontractors). Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities related to an executory contractual arrangement are deferred and capitalized. These advance payments are recognized as an expense as the related goods are delivered or services performed. When the related goods are no longer expected to be delivered or services rendered, the capitalized advance payment should be charged to expense. |
Leases | The Company determines if an arrangement contains a lease at inception based on whether there is an identified property, plant or equipment and whether the Company controls the use of the identified asset throughout the period of use. Operating leases are included in the accompanying consolidated balance sheets. Operating lease right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term. Lease liabilities represent the Company’s obligation to make lease payments arising from the lease and are included in current and non-current liabilities. Operating lease ROU assets and lease liabilities are recognized at the lease inception date based on the present value of lease payments over the lease term discounted based on the more readily determinable of (i) the rate implicit in the lease or (ii) the Company’s incremental borrowing rate (which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease). Because the Company’s operating leases generally do not provide an implicit rate, the Company estimates its incremental borrowing rate based on the information available at lease commencement date for borrowings with a similar term. The Company’s operating lease ROU assets are measured based on the corresponding operating lease liability adjusted for (i) payments made to the lessor at or before the commencement date, (ii) initial direct costs incurred and (iii) tenant incentives under the lease. The Company does not assume renewals or early terminations unless it is reasonably certain to exercise these options at commencement. The Company elected the practical expedient which allows the Company to not allocate consideration between lease and non-lease components. Variable lease payments |
Income Taxes | The Company accounts for income taxes in accordance with authoritative guidance, which requires the use of the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based upon the difference between the financial statement carrying amounts and the tax basis of assets and liabilities and are measured using the enacted tax rate expected to apply to taxable income in the years in which the differences are expected to be reversed. Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, management considers all available evidence, including past operating results, estimates of future taxable income, and the feasibility of tax planning strategies. In the event that management changes its determination as to the amount of deferred tax assets that can be realized, the Company will adjust its valuation allowance with a corresponding impact to the provision for income taxes in the period in which such determination is made. The Company is required to evaluate the tax positions taken in the course of preparing its tax returns to determine whether tax positions are “more-likely-than-not” of being sustained by the applicable tax authority. Tax benefits of positions not deemed to meet the “more likely than not” threshold would be recorded as a tax expense in the current year. The amount recognized is subject to estimate and management judgment with respect to the likely outcome of each uncertain tax position. The amount that is ultimately sustained for an individual uncertain tax position or for all uncertain tax positions in the aggregate could differ from the amount that is initially recognized. |
Concentrations of Risk | Financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and cash equivalents in banks that management believes are creditworthy, however deposits may exceed federally insured limits. |
Segment Reporting | Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing operating performance. In consideration of ASC Topic 280, Segment Reporting , we are not organized around specific services or geographic regions. Our chief operating decision maker “CODM” uses financial information to evaluate our performance, which is the same basis on which our results and performance are communicated to our Board of Directors. All of the Company’s long-lived assets are held domestically in the United States and of the $3.1 million of revenue recognized by the Company during the year ended December 31, 2023, 39% was derived from customers domiciled in foreign countries. Based on the information described above and in accordance with the applicable literature, management has concluded that we are organized and operated as one operating and reportable segment. |
Recently Adopted Accounting Standards | Although there are several new accounting pronouncements issued or proposed by the FASB, which have been adopted or will be adopted as applicable, management does not believe any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial position or results of operations. In July 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-03, Presentation of Financial Statements (Topic 205), Income Statement—Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation—Stock Compensation (Topic 718) (“ASU 2023-03”). This update requires to (1) disclosure and presentation of income or loss related to common stock transactions on the face of the income statement, (2) modification of the existing classification and measurement of redeemable preferred shares and redeemable equity-classified shares, and (3) modification of accounting treatment for stock-based compensation. The FASB has not set an effective date on ASU 2023-03 and adoption is permitted. The Company is currently evaluating the impact of the provisions of ASU 2023-03 on its consolidated financial statement disclosures. In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative (“ASU 2023-06”). The amendments in this ASU are expected to clarify or improve disclosure and presentation requirements of a variety of ASC topics by aligning them with the SEC’s regulations. ASU 2023-06 will become effective for each amendment on the effective date of the SEC's corresponding disclosure rule changes. The Company is currently evaluating the impact ASU 2023-06 will have on its consolidated results of operations, financial position, or cash flows. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. ASU 2023-07 requires disclosure of significant segment expenses that are regularly provided to the CODM and included within the reported measure of a segment’s profit or loss, requires interim disclosures about a reportable segment’s profit or loss and assets that are currently required annually, requires disclosure of the position and title of the CODM, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, and contains other disclosure requirements. ASU 2023-07 is scheduled to be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company is in the process of evaluating the potential impact the adoption of ASU 2023-07 will have on its consolidated results of operations, financial position, or cash flows. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”) that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in ASU 2023-09 must be applied on a retrospective basis to all prior periods presented in the consolidated financial statements and early adoption is permitted. The Company is in the process of evaluating the potential impact ASU 2023-09 will have on its results of consolidated operations, financial position, or cash flows. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Schedule of Property, Machinery and Equipment, Net | The estimated useful lives of fixed assets by asset category are described below: Fixed Assets Estimated Useful Life Computer equipment Three years Furniture and fixtures Five years Leasehold improvements Lesser of estimated useful life or remaining lease term (one year to seven years) Machinery and equipment Seven years Property, machinery and equipment, net consisted of the following: (in thousands) December 31, December 31, Computer equipment $ 10 $ 10 Leasehold improvements 2,394 2,281 Machinery and equipment 3,411 3,411 Construction in-progress — 106 Property, machinery and equipment, gross 5,815 5,808 Less: accumulated depreciation (2,563) (1,792) Property, machinery and equipment, net $ 3,252 $ 4,016 |
Schedule of Disaggregation of Revenue | The disaggregation of revenue by type is as follows: Year Ended (in thousands) 2023 2022 Transportation services $ 1,582 $ 127 Hosted payload services 568 — Forfeited customer deposits 641 172 Engineering project services 298 — Total revenue $ 3,089 $ 299 |
Schedule of Changes in Fair Value of Liabilities | The change in fair values of liabilities subject to recurring remeasurement were as follows: (in thousands) Level Fair value as of December 31, 2022 Payment of Stock Repurchase Liability Change in Fair Value Fair value as of December 31, 2023 Warrant Liability 3 $ 564 $ — $ (561) $ 3 Stock Repurchase Liability 3 10,000 (10,000) — — Total $ 10,564 $ (10,000) $ (561) $ 3 |
Schedule of Fair Value Inputs | Key assumptions for the Black-Scholes model used to determine the fair value of warrants outstanding as of December 31, 2023 were as follows: Warrant term (years) 2.61 Volatility 113.50 % Risk-free rate 4.05 % Dividend yield 0.00 % November Warrants Warrant term (years) 5.00 Volatility 86.00 % Risk-free rate 4.60 % Dividend yield 0.00 % Induced Warrants Before Modification After Modification Warrant term (years) 4.91 4.91 Volatility 89.00 % 89.00 % Risk-free rate 4.55 % 4.55 % Dividend yield 0.00 % 0.00 % October Warrants Warrant term (years) 5.00 Volatility 92.00 % Risk-free rate 4.67 % Dividend yield 0.00 % Before Modification After Modification February Class A Warrants and Series A Warrants Series B Warrants Modified Warrants Warrant term (years) 4.94 0.95 5.01 Volatility 88.00 % 86.00 % 89.00 % Risk-free rate 4.55 % 5.39 % 4.67 % Dividend yield 0.00 % 0.00 % 0.00 % Series A Warrants Series B Warrants Warrant term (years) 5.00 1.00 Volatility 85.00 % 79.00 % Risk-free rate 4.35 % 5.33 % Dividend yield 0.00 % 0.00 % Before Modification After Modification Warrant term (years) 4.97 5.01 Volatility 84.00 % 85.00 % Risk-free rate 4.40 % 4.33 % Dividend yield 0.00 % 0.00 % Warrant term (years) 5.51 Volatility 85.00 % Risk-free rate 4.03 % Dividend yield 0.00 % |
Prepaids and Other Current As_2
Prepaids and Other Current Assets (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Schedule of Prepaids and Other Current Assets | Prepaids and other current assets consisted of the following: (in thousands) December 31, December 31, Prepaid launch costs, current $ 1,260 $ 3,000 Prepaid research and development 2,415 2,841 Prepaid insurance and other assets 4,838 4,332 Total $ 8,513 $ 10,173 |
Property, Machinery and Equip_2
Property, Machinery and Equipment (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property, Machinery and Equipment, Net | The estimated useful lives of fixed assets by asset category are described below: Fixed Assets Estimated Useful Life Computer equipment Three years Furniture and fixtures Five years Leasehold improvements Lesser of estimated useful life or remaining lease term (one year to seven years) Machinery and equipment Seven years Property, machinery and equipment, net consisted of the following: (in thousands) December 31, December 31, Computer equipment $ 10 $ 10 Leasehold improvements 2,394 2,281 Machinery and equipment 3,411 3,411 Construction in-progress — 106 Property, machinery and equipment, gross 5,815 5,808 Less: accumulated depreciation (2,563) (1,792) Property, machinery and equipment, net $ 3,252 $ 4,016 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Intangible Assets, Net | Intangible assets, net consisted of the following as of December 31, 2023: (in thousands) Gross Value Accumulated Amortization Net Value Weighted Average Remaining Amortization Period (In Years) Patents/Intellectual Property $ 519 $ (177) $ 341 6.3 Total $ 519 $ (177) $ 341 Intangible assets, net consisted of the following as of December 31, 2022: (in thousands) Gross Value Accumulated Amortization Net Value Weighted Average Remaining Amortization Period (In Years) Patents/Intellectual Property $ 461 $ (124) $ 337 7.0 Total $ 461 $ (124) $ 337 |
Schedule of Future Estimated Amortization Expense | As of December 31, 2023, the future estimated amortization expense related to intangible assets is as follows: (in thousands) 2024 $ 58 2025 58 2026 58 2027 58 2028 49 Thereafter 60 Total $ 341 |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
Schedule of Components of Operating Lease Expense | The components of operating lease expense were as follows: Year Ended December 31, (in thousands) 2023 2022 Operating lease cost $ 1,470 $ 1,609 Variable lease expense 530 611 Short-term lease expense 62 38 Total lease expense $ 2,062 $ 2,258 |
Schedule of Maturities of Operating Lease Liabilities | As of December 31, 2023, the maturities of the Company’s operating lease liabilities were as follows: (in thousands) 2024 $ 1,580 2025 1,627 2026 1,674 2027 1,729 2028 297 Thereafter — Total lease payments 6,907 Less: Imputed interest (776) Present value of lease liabilities $ 6,131 |
Accrued Liabilities (Tables)
Accrued Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Expenses | Accrued expenses consisted of the following: (in thousands) December 31, December 31, Legal and other professional services $ 3,811 $ 3,128 Compensation expense 392 3,584 Research and development projects 323 981 Other accrued liabilities 228 333 Total $ 4,754 $ 8,026 |
Stockholders_ Equity (Tables)
Stockholders’ Equity (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Equity [Abstract] | |
Schedule of Fair Value Inputs | Key assumptions for the Black-Scholes model used to determine the fair value of warrants outstanding as of December 31, 2023 were as follows: Warrant term (years) 2.61 Volatility 113.50 % Risk-free rate 4.05 % Dividend yield 0.00 % November Warrants Warrant term (years) 5.00 Volatility 86.00 % Risk-free rate 4.60 % Dividend yield 0.00 % Induced Warrants Before Modification After Modification Warrant term (years) 4.91 4.91 Volatility 89.00 % 89.00 % Risk-free rate 4.55 % 4.55 % Dividend yield 0.00 % 0.00 % October Warrants Warrant term (years) 5.00 Volatility 92.00 % Risk-free rate 4.67 % Dividend yield 0.00 % Before Modification After Modification February Class A Warrants and Series A Warrants Series B Warrants Modified Warrants Warrant term (years) 4.94 0.95 5.01 Volatility 88.00 % 86.00 % 89.00 % Risk-free rate 4.55 % 5.39 % 4.67 % Dividend yield 0.00 % 0.00 % 0.00 % Series A Warrants Series B Warrants Warrant term (years) 5.00 1.00 Volatility 85.00 % 79.00 % Risk-free rate 4.35 % 5.33 % Dividend yield 0.00 % 0.00 % Before Modification After Modification Warrant term (years) 4.97 5.01 Volatility 84.00 % 85.00 % Risk-free rate 4.40 % 4.33 % Dividend yield 0.00 % 0.00 % Warrant term (years) 5.51 Volatility 85.00 % Risk-free rate 4.03 % Dividend yield 0.00 % |
Stock-based Compensation (Table
Stock-based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Schedule of Options Activity | The following table sets forth the summary of options activity, under the 2018 Plan and the 2021 Plans, for the year ended December 31, 2023: (in thousands, except share-based data) Total Options Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Term (In Years) Aggregate Intrinsic Value Outstanding as of December 31, 2022 51,166 $ 60.69 Vested exercised (10,081) $ 12.95 Forfeitures (17,173) $ 77.95 Outstanding as of December 31, 2023 23,912 $ 68.39 7.1 $ — Exercisable as of December 31, 2023 18,705 $ 54.36 6.8 $ — Vested and expected to vest as of December 31, 2023 23,912 $ 68.39 7.1 $ — |
Schedule of Restricted Stock Unit and Restricted Stock Award Activity | The following table sets forth the summary of RSU and RSA activity, under the Initial Plan, the 2018 Plan, the 2021 Plan, and the 2022 Plan, for the year ended December 31, 2023. RSAs were an immaterial portion of activity for the period: Shares Weighted Average Grant Date Fair Value (i.e. Share Price) Outstanding as of December 31, 2022 155,573 $ 199.74 Granted 212,089 27.26 Vested (42,701) 202.28 Forfeited (105,241) 86.95 Outstanding as of December 31, 2023 219,720 $ 86.78 |
Schedule of Stock-Based Compensation Expense | The following table sets forth the stock-based compensation under the Initial Plan, the 2018 Plan, the 2021 Plan, and the 2022 Plan by expense type: Year Ended December 31, (in thousands) 2023 2022 Research and development expenses $ 2,131 $ 2,134 Selling, general and administrative expenses 6,349 9,446 Total $ 8,480 $ 11,580 The following table sets forth the stock-based compensation under the Initial Plan, the 2018 Plan, the 2021 Plan, and the 2022 Plan by award type: Year Ended December 31, (in thousands) 2023 2022 Options $ 352 $ 538 RSUs & RSAs 8,115 10,995 ESPP 13 117 Performance Awards — (70) Total $ 8,480 $ 11,580 |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Earnings Per Share [Abstract] | |
Schedule of Antidilutive Shares | The following table summarizes potential common shares that were excluded as their effect is anti-dilutive: Year Ended December 31, 2023 2022 Options and unvested stock units outstanding 243,911 127,116 Warrants outstanding 6,206,488 399,149 Contingent Sponsor Earnout Shares 28,750 28,750 Total 6,479,149 555,015 |
Commitment and Contingencies (T
Commitment and Contingencies (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Future Unconditional Purchase Obligations | As of December 31, 2023, the Company’s future unconditional purchase obligations are as follows: (in thousands) 2024 $ 2,597 Total $ 2,597 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Schedule of Effective Income Tax Rate Reconciliation | The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate for the years ended December 31, 2023 and 2022: (in thousands) December 31, 2023 December 31, 2022 Tax provision (benefit) at U.S. statutory rate $ (14,473) 21.0 % $ (20,042) 21.0 % State income taxes, net of federal benefit $ (6,694) 9.7 % $ 11,113 (11.6) % Non-deductible expenses 261 (0.4) % (60) 0.1 % Change in value of equity instruments (118) 0.2 % (1,089) 1.1 % Deferred adjustments (56) 0.1 % (143) 0.2 % Other (172) 0.3 % — — % Research and development credits (274) 0.4 % (1,085) 1.1 % IRC Sec. 174 217 (0.3) % — — % Uncertain tax positions 69 (0.1) % 276 (0.3) % Change in valuation allowance 21,240 (30.8) % 11,030 (11.6) % $ — — % $ — — % |
Schedule of Deferred Tax Assets and Liabilities | The following table presents the significant components of the Company’s deferred tax assets and liabilities as of December 31, 2023 and 2022: (in thousands) December 31, December 31, Deferred tax assets: Net operating loss carryforwards $ 37,037 $ 16,562 Start-up and Organization Costs 16,913 16,965 Capitalized research and development credits 10,943 17,922 Intangibles 6,703 22 Stock-based compensation 4,972 3,072 Research and development credits 4,842 4,595 Operating lease obligations 1,375 1,534 Accrued expenses and reserves 621 1,710 Property and equipment 233 173 Other 1 1 Total deferred tax assets before valuation allowance 83,640 62,556 Valuation allowance (82,440) (61,200) Total deferred tax assets $ 1,200 $ 1,356 Deferred Tax Liabilities: Operating lease right-of-use assets $ (1,200) $ (1,356) Total deferred tax liabilities $ (1,200) $ (1,356) Net deferred tax assets $ — $ — |
Schedule of Unrecognized Tax Benefits | The following table summarizes the activity related to the Company’s gross unrecognized tax benefits: (in thousands) Gross unrecognized tax benefits Balance as of December 31, 2022 $ 1,712 Increases related to prior tax positions (29) Increases related to current tax positions 96 Balance as of December 31, 2023 $ 1,779 |
Nature of Operations (Details)
Nature of Operations (Details) $ in Thousands | 12 Months Ended | |||||
Aug. 22, 2023 | Aug. 12, 2021 USD ($) | Dec. 31, 2023 USD ($) satellite mission | Dec. 31, 2022 USD ($) | Nov. 11, 2023 payload satellite | May 25, 2022 satellite | |
Schedule of Reverse Recapitalization [Line Items] | ||||||
Number of customer satellites in low earth orbit | satellite | 8 | |||||
Number of customer satellites in low earth orbit, vigoride | satellite | 7 | |||||
Number of third-party customer satellites deployed in low earth orbit | satellite | 1 | |||||
Number of payloads | payload | 5 | |||||
Number of customer payloads | payload | 4 | |||||
Number of customers with satellites not deployed | payload | 3 | |||||
Number of remaining customer satellites | satellite | 3 | |||||
Number of spacecraft missions | mission | 4 | |||||
Number of customer satellites deployed in orbit | satellite | 17 | |||||
Additional funding received in connection with business combination | $ | $ 247,300 | |||||
Net loss | $ | $ 68,920 | $ 95,444 | ||||
Accumulated deficit | $ | 373,047 | 304,127 | ||||
Net cash used in operating activities | $ | 61,826 | 87,887 | ||||
Cash and cash equivalents | $ | $ 2,118 | $ 61,094 | ||||
Common Class A | ||||||
Schedule of Reverse Recapitalization [Line Items] | ||||||
Stock split ratio | 0.2 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Narrative (Details) | 3 Months Ended | 12 Months Ended | ||||
Aug. 12, 2021 USD ($) | Mar. 31, 2023 USD ($) | Dec. 31, 2023 USD ($) segment $ / shares shares | Dec. 31, 2022 USD ($) | Nov. 09, 2023 $ / shares | Nov. 08, 2023 shares | |
Cash and Cash Equivalents [Line Items] | ||||||
Restricted cash, non-current | $ 373,000 | $ 312,000 | ||||
Deferred fulfillment and prepaid launch costs | 1,700,000 | 7,400,000 | ||||
Deferred offering costs | 300,000 | |||||
Contract with customer, cumulative catch-up to revenue | 300,000 | 0 | ||||
Contract with customer, liability | 1,000,000 | 2,700,000 | ||||
Contract liabilities, non-current | 998,000 | 1,026,000 | ||||
Service revenue | 3,089,000 | 299,000 | ||||
Revenue recognized previously recorded as contract liability | $ 3,100,000 | |||||
Contract with customer, liability | 1,800,000 | |||||
Warrant term (years) | 5 years | |||||
Payment of liability | $ 10,000,000 | |||||
Number of warrants outstanding (in shares) | shares | 1,716,000 | |||||
Exercise price (in dollars per share) | $ / shares | $ 2 | |||||
Estimated fair value of warrants | $ 3,000 | 564,000 | ||||
Impairments of long-lived assets | 0 | 0 | ||||
Defined contribution plan, cost | $ 0 | 0 | ||||
Number of reportable segments | segment | 1 | |||||
Number of operating segments | segment | 1 | |||||
Revenue from Contract with Customer Benchmark | Geographic Concentration Risk | Geographic Distribution, Foreign | ||||||
Cash and Cash Equivalents [Line Items] | ||||||
Percentage of derived from customers | 39% | |||||
Common Class A | ||||||
Cash and Cash Equivalents [Line Items] | ||||||
Exchange ratio | 1 | |||||
Exercise price (in dollars per share) | $ / shares | $ 575 | |||||
Expiration period | 5 years | |||||
ESPP | ||||||
Cash and Cash Equivalents [Line Items] | ||||||
Offering period | 6 months | |||||
Restricted Stock Units | ||||||
Cash and Cash Equivalents [Line Items] | ||||||
ESPP expected term | 6 months | |||||
Private Placement Warrant | ||||||
Cash and Cash Equivalents [Line Items] | ||||||
Number of warrants outstanding (in shares) | shares | 225,450 | |||||
Estimated fair value of warrants | $ 31,200,000 | |||||
Public Warrant | ||||||
Cash and Cash Equivalents [Line Items] | ||||||
Number of warrants outstanding (in shares) | shares | 172,500 | |||||
Equity related to warrants | $ 20,200,000 | |||||
Prepaid Expenses and Other Current Assets | ||||||
Cash and Cash Equivalents [Line Items] | ||||||
Deferred fulfillment and prepaid launch costs | $ 1,300,000 | 3,000,000 | ||||
Other Noncurrent Assets | ||||||
Cash and Cash Equivalents [Line Items] | ||||||
Deferred fulfillment and prepaid launch costs | 400,000 | $ 4,400,000 | ||||
Operating Expense | ||||||
Cash and Cash Equivalents [Line Items] | ||||||
Write off prepaid launch cost | $ 3,700,000 | |||||
Patents | ||||||
Cash and Cash Equivalents [Line Items] | ||||||
Intangible asset useful life | 10 years | |||||
Cash Designated for Collateral | ||||||
Cash and Cash Equivalents [Line Items] | ||||||
Restricted cash, non-current | $ 400,000 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Schedule of Property, Machinery and Equipment, net (Details) | Dec. 31, 2023 |
Computer equipment | |
Property, Plant and Equipment [Line Items] | |
Estimated Useful Life | 3 years |
Furniture and fixtures | |
Property, Plant and Equipment [Line Items] | |
Estimated Useful Life | 5 years |
Leasehold improvements | Minimum | |
Property, Plant and Equipment [Line Items] | |
Estimated Useful Life | 1 year |
Leasehold improvements | Maximum | |
Property, Plant and Equipment [Line Items] | |
Estimated Useful Life | 7 years |
Machinery and equipment | |
Property, Plant and Equipment [Line Items] | |
Estimated Useful Life | 7 years |
Summary of Significant Accoun_6
Summary of Significant Accounting Policies - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Disaggregation of Revenue [Line Items] | ||
Service revenue | $ 3,089 | $ 299 |
Transportation services | ||
Disaggregation of Revenue [Line Items] | ||
Service revenue | 1,582 | 127 |
Hosted payload services | ||
Disaggregation of Revenue [Line Items] | ||
Service revenue | 568 | 0 |
Forfeited customer deposits | ||
Disaggregation of Revenue [Line Items] | ||
Service revenue | 641 | 172 |
Engineering project services | ||
Disaggregation of Revenue [Line Items] | ||
Service revenue | $ 298 | $ 0 |
Summary of Significant Accoun_7
Summary of Significant Accounting Policies - Schedule of Changes in Fair Value of Liabilities (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2023 USD ($) | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |
Fair value recurring, basis unobservable input reconciliation, liability gain (loss), statement of other comprehensive income, extensible list, not disclosed flag | Change in Fair Value |
Fair Value, Inputs, Level 3 | Fair Value, Recurring | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |
Fair value at beginning of period | $ 10,564 |
Stock Repurchase Liability | (10,000) |
Warrant Liability | (561) |
Fair value at end of period | 3 |
Fair Value, Inputs, Level 3 | Warrant Liability | Fair Value, Recurring | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |
Fair value at beginning of period | 564 |
Warrant Liability | (561) |
Fair value at end of period | 3 |
Fair Value, Inputs, Level 3 | Stock Repurchase Liability | Fair Value, Recurring | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |
Fair value at beginning of period | 10,000 |
Stock Repurchase Liability | (10,000) |
Fair value at end of period | $ 0 |
Summary of Significant Accoun_8
Summary of Significant Accounting Policies - Schedule of Fair Value Inputs (Details) | Dec. 31, 2023 |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Warrant term (years) | 5 years |
Warrant term (years) | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Warrant term (years) | 2 years 7 months 9 days |
Volatility | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Warrants, measurement input | 1.1350 |
Risk-free rate | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Warrants, measurement input | 0.0405 |
Dividend yield | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Warrants, measurement input | 0 |
Prepaids and Other Current As_3
Prepaids and Other Current Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | ||
Prepaid launch costs, current | $ 1,260 | $ 3,000 |
Prepaid research and development | 2,415 | 2,841 |
Prepaid insurance and other assets | 4,838 | 4,332 |
Prepaids and other current assets | 8,513 | 10,173 |
Non-current portion of prepaid launch costs | $ 400 | $ 4,400 |
Property, Machinery and Equip_3
Property, Machinery and Equipment (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Property, Plant and Equipment [Line Items] | ||
Property, machinery and equipment, gross | $ 5,815 | $ 5,808 |
Less: accumulated depreciation | (2,563) | (1,792) |
Property, machinery and equipment, net | 3,252 | 4,016 |
Depreciation expense | 800 | 1,000 |
Computer equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property, machinery and equipment, gross | 10 | 10 |
Leasehold improvements | ||
Property, Plant and Equipment [Line Items] | ||
Property, machinery and equipment, gross | 2,394 | 2,281 |
Machinery and equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property, machinery and equipment, gross | 3,411 | 3,411 |
Construction in-progress | ||
Property, Plant and Equipment [Line Items] | ||
Property, machinery and equipment, gross | $ 0 | $ 106 |
Intangible Assets - Schedule of
Intangible Assets - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Finite-Lived Intangible Assets [Line Items] | ||
Gross Value | $ 519 | $ 461 |
Accumulated Amortization | (177) | (124) |
Net Value | 341 | 337 |
Patents/Intellectual Property | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Value | 519 | 461 |
Accumulated Amortization | (177) | (124) |
Net Value | $ 341 | $ 337 |
Weighted Average Remaining Amortization Period (In Years) | 6 years 3 months 18 days | 7 years |
Intangible Assets - Narrative (
Intangible Assets - Narrative (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Amortization expense | $ 50 | $ 110 |
Intangible Assets - Schedule _2
Intangible Assets - Schedule of Future Estimated Amortization Expense (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] | ||
2024 | $ 58 | |
2025 | 58 | |
2026 | 58 | |
2027 | 58 | |
2028 | 49 | |
Thereafter | 60 | |
Net Value | $ 341 | $ 337 |
Leases - Narrative (Details)
Leases - Narrative (Details) $ in Thousands | Dec. 31, 2023 USD ($) | Nov. 30, 2022 lease | Dec. 30, 2021 lease | Jan. 31, 2021 USD ($) |
Leases [Abstract] | ||||
Obligation owed under lease agreement | $ | $ 6,907 | $ 10,500 | ||
Number of leases modified | 2 | |||
Lessee, operating lease, number of leases expired | 1 | |||
Operating lease, weighted-average remaining lease term | 4 years 2 months 12 days | |||
Operating lease, weighted-average discount rate | 5.60% |
Leases - Schedule of Components
Leases - Schedule of Components of Operating Lease Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Leases [Abstract] | ||
Operating lease cost | $ 1,470 | $ 1,609 |
Variable lease expense | 530 | 611 |
Short-term lease expense | 62 | 38 |
Total lease expense | $ 2,062 | $ 2,258 |
Leases - Schedule of Maturities
Leases - Schedule of Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Jan. 31, 2021 |
Lessee, Operating Lease, Liability, Payment, Due [Abstract] | ||
2024 | $ 1,580 | |
2025 | 1,627 | |
2026 | 1,674 | |
2027 | 1,729 | |
2028 | 297 | |
Thereafter | 0 | |
Total lease payments | 6,907 | $ 10,500 |
Less: Imputed interest | (776) | |
Present value of lease liabilities | $ 6,131 |
Accrued Liabilities (Details)
Accrued Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Payables and Accruals [Abstract] | ||
Legal and other professional services | $ 3,811 | $ 3,128 |
Compensation expense | 392 | 3,584 |
Research and development projects | 323 | 981 |
Other accrued liabilities | 228 | 333 |
Accrued liabilities | $ 4,754 | $ 8,026 |
Loan Payable (Details)
Loan Payable (Details) - Term Loan - USD ($) | 12 Months Ended | ||
Feb. 22, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | |
Short-term Debt [Line Items] | |||
Initial borrowing capacity | $ 40,000,000 | ||
Interest rate | 12% | ||
Proceeds from short-term borrowings | $ 25,000,000 | ||
Amount no longer available for borrowing | $ 15,000,000 | ||
Debt term | 2 years | ||
Unamortized debt discount | $ 15,800,000 | ||
Percentage of debt discount in excess of initial face value | 63% | ||
Calculated effective interest rate | 126% | 28.20% | |
Interest expense amortization | $ 1,400,000 | $ 2,700,000 | |
Loans payable | 2,300,000 | ||
Unamortized debt discount and issuance costs | 45,700 | ||
Long-term debt, due in 2024 | $ 2,300,000 |
Stockholders_ Equity - Narrativ
Stockholders’ Equity - Narrative (Details) | 3 Months Ended | 12 Months Ended | ||||||||||||||||||
Nov. 09, 2023 USD ($) $ / shares shares | Nov. 08, 2023 shares | Oct. 04, 2023 USD ($) | Oct. 02, 2023 USD ($) $ / shares shares | Sep. 11, 2023 USD ($) | Sep. 07, 2023 USD ($) $ / shares shares | Aug. 22, 2023 $ / shares shares | Feb. 27, 2023 USD ($) | Feb. 23, 2023 $ / shares shares | Sep. 28, 2022 USD ($) | Aug. 13, 2021 $ / shares shares | Aug. 12, 2021 USD ($) | Jun. 30, 2021 USD ($) | Mar. 31, 2023 USD ($) | Dec. 31, 2023 USD ($) $ / shares shares | Dec. 31, 2022 USD ($) $ / shares shares | Nov. 06, 2023 $ / shares shares | Oct. 01, 2023 | Sep. 10, 2023 | Mar. 31, 2022 shares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Shares of stock authorized (in shares) | 274,312,500 | |||||||||||||||||||
Preferred stock, number of shares authorized (in shares) | 20,000,000 | 20,000,000 | ||||||||||||||||||
Preferred stock, par value (in dollars per share) | $ / shares | $ 0.00001 | $ 0.00001 | ||||||||||||||||||
Number of warrants exercised on net basis (in shares) | 2,904,269 | |||||||||||||||||||
Exercise price (in dollars per share) | $ / shares | $ 2 | |||||||||||||||||||
Warrant term (years) | 5 years | |||||||||||||||||||
Proceeds from issuance of warrants | $ | $ 6,500,000 | $ 3,600,000 | $ 4,600,000 | $ 9,300,000 | ||||||||||||||||
Offering fees and other expenses payable | $ | $ 500,000 | |||||||||||||||||||
Warrants consideration (in dollars per share) | $ / shares | $ 0.25 | |||||||||||||||||||
Proceeds from exercise of warrants | $ | $ 6,000,000 | $ 7,881,000 | $ 0 | |||||||||||||||||
Shares issued upon exercise of warrant (in shares) | 1,188,269 | |||||||||||||||||||
Number of warrants outstanding (in shares) | 1,716,000 | |||||||||||||||||||
Aggregate cost | $ | 4,000,000 | 5,000,000 | 10,000,000 | |||||||||||||||||
Agent fees and other offering costs | $ | $ 400,000 | $ 400,000 | 700,000 | 2,048,000 | 0 | |||||||||||||||
Percentage of equity interest sold by co-founders | 100% | |||||||||||||||||||
Additional payments owed to co-founders | $ | 10,000,000 | $ 10,000,000 | ||||||||||||||||||
Minimum proceeds from sale of business and other capital raising transactions | $ | 250,000,000 | |||||||||||||||||||
Additional funding received in connection with business combination | $ | $ 247,300,000 | |||||||||||||||||||
Payment of liability | $ | $ 10,000,000 | |||||||||||||||||||
Change in fair value of warrant liability | $ | (561,000) | (5,185,000) | ||||||||||||||||||
Deferred offering costs | $ | 300,000 | |||||||||||||||||||
ATM Sales Agreement | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Aggregate cost | $ | $ 0 | |||||||||||||||||||
Commission rate percentage | 3% | |||||||||||||||||||
Consideration From Funds Legally Available | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Additional payments owed to co-founders | $ | $ 40,000,000 | |||||||||||||||||||
Common Stock | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Number of shares sold (in shares) | 187,920 | |||||||||||||||||||
Purchase price (in dollars per share) | $ / shares | $ 43.23 | |||||||||||||||||||
Aggregate cost | $ | $ 10,000,000 | |||||||||||||||||||
November Warrants | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Number of warrants exercised on net basis (in shares) | 5,808,538 | |||||||||||||||||||
Exercise price (in dollars per share) | $ / shares | $ 3.86 | |||||||||||||||||||
Warrant term (years) | 5 years | |||||||||||||||||||
Series A Warrants | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Number of warrants exercised on net basis (in shares) | 672,948 | 672,948 | ||||||||||||||||||
Exercise price (in dollars per share) | $ / shares | $ 7.18 | |||||||||||||||||||
Warrant term (years) | 5 years | 4 years 11 months 8 days | ||||||||||||||||||
February Class A Warrants | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Number of warrants exercised on net basis (in shares) | 231,321 | 231,321 | ||||||||||||||||||
Exercise price (in dollars per share) | $ / shares | $ 7.18 | $ 57.50 | ||||||||||||||||||
Warrant term (years) | 5 years 3 days | 5 years 6 months 3 days | 4 years 11 months 19 days | |||||||||||||||||
Equity related to warrants | $ | $ 600,000 | |||||||||||||||||||
October Warrants | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Number of warrants exercised on net basis (in shares) | 2,000,000 | 2,000,000 | ||||||||||||||||||
Exercise price (in dollars per share) | $ / shares | $ 2 | |||||||||||||||||||
Warrant term (years) | 5 years | |||||||||||||||||||
Estimated fair value of warrants | $ | $ 500,000 | |||||||||||||||||||
Equity related to warrants | $ | $ 1,000,000 | |||||||||||||||||||
Prefunded Warrants | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Number of warrants exercised on net basis (in shares) | 1,710,000 | 462,948 | ||||||||||||||||||
Exercise price (in dollars per share) | $ / shares | $ 0.00001 | $ 0.00001 | ||||||||||||||||||
Prefunded Warrants | Warrants | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Exercise price (in dollars per share) | $ / shares | $ 0.00001 | |||||||||||||||||||
Number of shares sold (in shares) | 43,401 | |||||||||||||||||||
Series B Warrants | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Number of warrants exercised on net basis (in shares) | 672,948 | 672,948 | ||||||||||||||||||
Exercise price (in dollars per share) | $ / shares | $ 7.18 | |||||||||||||||||||
Warrant term (years) | 1 year | 11 months 12 days | ||||||||||||||||||
Proceeds from exercise of warrants | $ | $ 1,300,000 | |||||||||||||||||||
Public Warrant | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Number of warrants outstanding (in shares) | 172,500 | |||||||||||||||||||
Equity related to warrants | $ | $ 20,200,000 | |||||||||||||||||||
Private Placement Warrant | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Number of warrants outstanding (in shares) | 225,450 | |||||||||||||||||||
Other Warrants | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Number of warrants exercised on net basis (in shares) | 5,563 | |||||||||||||||||||
Exercise price (in dollars per share) | $ / shares | $ 10 | |||||||||||||||||||
Number of warrants outstanding (in shares) | 6,171 | |||||||||||||||||||
Private Warrant | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Change in fair value of warrant liability | $ | $ (600,000) | $ (5,200,000) | ||||||||||||||||||
October Pre-Funded Warrants | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Number of warrants exercised on net basis (in shares) | 1,710,000 | |||||||||||||||||||
September Prefunded Warrants | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Number of warrants exercised on net basis (in shares) | 462,948 | |||||||||||||||||||
February Prefunded Warrants | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Number of warrants exercised on net basis (in shares) | 43,401 | |||||||||||||||||||
Common Class A | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Stock split ratio | 0.2 | |||||||||||||||||||
Common stock, number of shares authorized (in shares) | 250,000,000 | 250,000,000 | 250,000,000 | |||||||||||||||||
Common stock, par value (in dollars per share) | $ / shares | $ 0.00001 | $ 0.00001 | $ 0.00001 | |||||||||||||||||
Exercise price (in dollars per share) | $ / shares | $ 575 | |||||||||||||||||||
Number of shares sold (in shares) | 290,000 | 210,000 | ||||||||||||||||||
Purchase price (in dollars per share) | $ / shares | $ 2 | $ 7.43 | ||||||||||||||||||
Common Class A | ATM Sales Agreement | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Aggregate cost | $ | $ 50,000,000 | |||||||||||||||||||
Common Class A | Contingent Sponsor Earnout Shares | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Number of shares modified (in shares) | 28,750 | |||||||||||||||||||
Common Class A | Contingent Sponsor Earnout Shares | Weighted Average Closing Price of $12.50 | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Weighted-average closing sale price (in dollars per share) | $ / shares | $ 625 | |||||||||||||||||||
Percentage of shares forfeited | 66% | |||||||||||||||||||
Common Class A | Contingent Sponsor Earnout Shares | Weighted Average Closing Price of $15.00 | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Weighted-average closing sale price (in dollars per share) | $ / shares | $ 750 | |||||||||||||||||||
Percentage of shares forfeited | 33% | |||||||||||||||||||
Common Class A | Contingent Sponsor Earnout Shares | Weighted Average Closing Price of $17.50 | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Weighted-average closing sale price (in dollars per share) | $ / shares | $ 875 | |||||||||||||||||||
Common Class A | Common Stock | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Shares issued upon exercise of warrant (in shares) | 3,577,217 | 5,563 | ||||||||||||||||||
Common Class B | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Common stock, number of shares authorized (in shares) | 4,312,500 | 4,312,500 | 4,312,500 | |||||||||||||||||
Common stock, par value (in dollars per share) | $ / shares | $ 0.00001 | $ 0.00001 | $ 0.00001 | |||||||||||||||||
Preferred Stock | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||||||||
Preferred stock, number of shares authorized (in shares) | 20,000,000 | |||||||||||||||||||
Preferred stock, par value (in dollars per share) | $ / shares | $ 0.00001 |
Stockholders_ Equity - Schedule
Stockholders’ Equity - Schedule of Fair Value Inputs (Details) | Dec. 31, 2023 | Nov. 09, 2023 | Nov. 08, 2023 | Nov. 06, 2023 | Oct. 02, 2023 | Oct. 01, 2023 | Sep. 11, 2023 | Sep. 10, 2023 | Sep. 07, 2023 | Feb. 23, 2023 |
Class of Warrant or Right [Line Items] | ||||||||||
Warrant term (years) | 5 years | |||||||||
Risk-free rate | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0.0405 | |||||||||
Dividend yield | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0 | |||||||||
November Warrants | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrant term (years) | 5 years | |||||||||
November Warrants | Volatility | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0.8600 | |||||||||
November Warrants | Risk-free rate | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0.0460 | |||||||||
November Warrants | Dividend yield | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0 | |||||||||
Induced Warrants | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrant term (years) | 4 years 10 months 28 days | 4 years 10 months 28 days | ||||||||
Induced Warrants | Volatility | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0.8900 | 0.8900 | ||||||||
Induced Warrants | Risk-free rate | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0.0455 | 0.0455 | ||||||||
Induced Warrants | Dividend yield | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0 | 0 | ||||||||
Series A Warrants | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrant term (years) | 4 years 11 months 8 days | 5 years | ||||||||
Series A Warrants | Volatility | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0.8800 | 0.8500 | ||||||||
Series A Warrants | Risk-free rate | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0.0455 | 0.0435 | ||||||||
Series A Warrants | Dividend yield | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0 | 0 | ||||||||
Series B Warrants | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrant term (years) | 11 months 12 days | 1 year | ||||||||
Series B Warrants | Volatility | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0.8600 | 0.7900 | ||||||||
Series B Warrants | Risk-free rate | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0.0539 | 0.0533 | ||||||||
Series B Warrants | Dividend yield | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0 | 0 | ||||||||
Modified Warrants | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrant term (years) | 5 years 3 days | |||||||||
Modified Warrants | Volatility | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0.8900 | |||||||||
Modified Warrants | Risk-free rate | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0.0467 | |||||||||
Modified Warrants | Dividend yield | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0 | |||||||||
October Warrants | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrant term (years) | 5 years | |||||||||
October Warrants | Volatility | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0.9200 | |||||||||
October Warrants | Risk-free rate | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0.0467 | |||||||||
October Warrants | Dividend yield | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0 | |||||||||
February Class A Warrants | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrant term (years) | 5 years 3 days | 4 years 11 months 19 days | 5 years 6 months 3 days | |||||||
February Class A Warrants | Volatility | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0.8500 | 0.8400 | 0.8500 | |||||||
February Class A Warrants | Risk-free rate | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0.0433 | 0.0440 | 0.0403 | |||||||
February Class A Warrants | Dividend yield | ||||||||||
Class of Warrant or Right [Line Items] | ||||||||||
Warrants, measurement input | 0 | 0 | 0 |
Stock-based Compensation - Narr
Stock-based Compensation - Narrative (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
Aug. 12, 2021 | Feb. 28, 2022 | Dec. 31, 2023 | Jun. 30, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | May 08, 2023 | Mar. 22, 2023 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Options vested exercised, aggregate intrinsic value | $ 200,000 | $ 5,100,000 | ||||||
Issuance of common stock for consulting services | 112,000 | |||||||
Consulting expense | 8,480,000 | 11,580,000 | ||||||
Share-Based Payment Arrangement, Nonemployee | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Issuance of common stock for consulting services (in shares) | 0 | |||||||
Issuance of common stock for consulting services | $ 100,000 | |||||||
Expiration period | 6 months | |||||||
Consulting expense | $ (100,000) | |||||||
Share-Based Payment Arrangement, Nonemployee | Common Class A | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Issuance of common stock for consulting services (in shares) | 2,700 | |||||||
Restricted Stock Units | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Unrecognized compensation cost, period of recognition | 1 year 3 months 18 days | |||||||
Unrecognized compensation cost | $ 14,100,000 | $ 14,100,000 | ||||||
Options | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Unrecognized compensation cost for unvested options | 300,000 | $ 300,000 | ||||||
Unrecognized compensation cost, period of recognition | 1 year 1 month 6 days | |||||||
Consulting expense | $ 352,000 | 538,000 | ||||||
Outstanding Vested and Expected to Vest RSUs | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Unrecognized compensation cost | $ 400,000 | $ 400,000 | ||||||
Performance Awards | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Number of shares that would have been settled (in shares) | 0 | 0 | ||||||
Consulting expense | $ 0 | $ (70,000) | ||||||
2021 Equity Incentive Plan | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Evergreen provision, percentage of outstanding shares | 3% | |||||||
2021 Equity Incentive Plan | Common Class A | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Number of shares reserved for future issuance (in shares) | 119,658 | |||||||
2021 Equity Incentive Plan | Restricted Stock Units | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Remaining shares available for grant (in shares) | 45,721 | 45,721 | ||||||
Evergreen Plan | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Number of additional shares available for grant (in shares) | 50,664 | |||||||
Legacy Stock Plan | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Number of additional shares available for grant (in shares) | 7,473 | |||||||
2021 Employee Stock Purchase Plan | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Evergreen provision, percentage of outstanding shares | 0.50% | |||||||
Number of additional shares available for grant (in shares) | 8,444 | |||||||
Remaining shares available for grant (in shares) | 41,936 | 41,936 | ||||||
Issuance of common stock upon purchase of ESPP (in shares) | 3,230 | |||||||
Outstanding liability | $ 13,600 | $ 13,600 | ||||||
2021 Employee Stock Purchase Plan | Common Class A | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Number of shares reserved for future issuance (in shares) | 31,909 | |||||||
2022 Inducement Equity Plan | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Remaining shares available for grant (in shares) | 60,952 | 60,952 | ||||||
Vesting period | 4 years | |||||||
2022 Inducement Equity Plan | Common Class A | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Number of shares reserved for future issuance (in shares) | 80,000 | 160,000 | 140,000 |
Stock-based Compensation - Sche
Stock-based Compensation - Schedule of Options Activity (Details) $ / shares in Units, $ in Thousands | 12 Months Ended |
Dec. 31, 2023 USD ($) $ / shares shares | |
Total Options | |
Beginning balance (in shares) | shares | 51,166 |
Vested exercised (in shares) | shares | (10,081) |
Forfeitures (in shares) | shares | (17,173) |
Ending balance (in shares) | shares | 23,912 |
Total options exercisable (in shares) | shares | 18,705 |
Weighted- Average Exercise Price Per Share | |
Options outstanding, weighted-average exercise price per share, beginning balance (in dollars per share) | $ / shares | $ 60.69 |
Vested exercised (in dollars per share) | $ / shares | 12.95 |
Forfeitures (in dollars per share) | $ / shares | 77.95 |
Options outstanding, weighted-average exercise price per share, ending balance (in dollars per share) | $ / shares | 68.39 |
Options exercisable, weighted-average exercise price per share (in dollars per share) | $ / shares | $ 54.36 |
Stock Options Additional Disclosures | |
Options outstanding, weighted-average remaining contractual term (in years) | 7 years 1 month 6 days |
Options exercisable, weighted-average remaining contractual term (in years) | 6 years 9 months 18 days |
Options outstanding, aggregate intrinsic value | $ | $ 0 |
Options exercisable, aggregate intrinsic value | $ | $ 0 |
Vested and Expected to Vest | |
Total options vested and expected to vest (in shares) | shares | 23,912 |
Options vested and expected to vest, weighted-average exercise price per share (in dollars per share) | $ / shares | $ 68.39 |
Options vested and expected to vest, weighted-average remaining contractual term (in years) | 7 years 1 month 6 days |
Options vested and expected to vest, aggregate intrinsic value | $ | $ 0 |
Stock-based Compensation - Sc_2
Stock-based Compensation - Schedule of Restricted Stock Units Activity (Details) - RSUs & RSAs | 12 Months Ended |
Dec. 31, 2023 $ / shares shares | |
Shares | |
Balance at the beginning of the period (in shares) | shares | 155,573 |
Granted (in shares) | shares | 212,089 |
Vested (in shares) | shares | (42,701) |
Forfeited (in shares) | shares | (105,241) |
Balance at the end of the period (in shares) | shares | 219,720 |
Weighted Average Grant Date Fair Value (i.e. Share Price) | |
Balance at the beginning of the period (in dollars per share) | $ / shares | $ 199.74 |
Granted (in dollars per share) | $ / shares | 27.26 |
Vested (in dollars per share) | $ / shares | 202.28 |
Forfeited (in dollars per share) | $ / shares | 86.95 |
Balance at the end of the period (in dollars per share) | $ / shares | $ 86.78 |
Stock-based Compensation - Sc_3
Stock-based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Consulting expense | $ 8,480 | $ 11,580 |
Options | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Consulting expense | 352 | 538 |
RSUs & RSAs | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Consulting expense | 8,115 | 10,995 |
ESPP | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Consulting expense | 13 | 117 |
Performance Awards | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Consulting expense | 0 | (70) |
Research and development expenses | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Consulting expense | 2,131 | 2,134 |
Selling, general and administrative expenses | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Consulting expense | $ 6,349 | $ 9,446 |
Earnings Per Share - Schedule o
Earnings Per Share - Schedule of Antidilutive Shares (Details) - shares | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total (in shares) | 6,479,149 | 555,015 |
Options and unvested stock units outstanding | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total (in shares) | 243,911 | 127,116 |
Warrants outstanding | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total (in shares) | 6,206,488 | 399,149 |
Contingent Sponsor Earnout Shares | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total (in shares) | 28,750 | 28,750 |
Commitment and Contingencies -
Commitment and Contingencies - Schedule of Unconditional Purchase Obligations (Details) $ in Thousands | Dec. 31, 2023 USD ($) |
Unrecorded Unconditional Purchase Obligation, Fiscal Year Maturity [Abstract] | |
2024 | $ 2,597 |
Total | $ 2,597 |
Commitment and Contingencies _2
Commitment and Contingencies - Narrative (Details) - USD ($) | 12 Months Ended | |||||||||
Oct. 23, 2023 | Oct. 18, 2023 | Oct. 05, 2023 | Oct. 02, 2023 | Sep. 07, 2023 | Feb. 27, 2023 | Jul. 20, 2022 | Jun. 30, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | |
Loss Contingencies [Line Items] | ||||||||||
Other expense | $ (748,000) | $ (4,169,000) | ||||||||
Percentage of equity interest sold by co-founders | 100% | |||||||||
Payments to co-founders | $ 40,000,000 | |||||||||
Additional payments owed to co-founders | $ 10,000,000 | 10,000,000 | ||||||||
Minimum proceeds from sale of business and other capital raising transactions | 250,000,000 | |||||||||
Aggregate cost | $ 4,000,000 | $ 5,000,000 | $ 10,000,000 | |||||||
Consideration Due within 10 Business Days | ||||||||||
Loss Contingencies [Line Items] | ||||||||||
Additional payments owed to co-founders | $ 10,000,000 | |||||||||
Threshold period | 10 days | |||||||||
Minimum proceeds from sale of business and other capital raising transactions | $ 250,000,000 | |||||||||
Baker Mckenzie | ||||||||||
Loss Contingencies [Line Items] | ||||||||||
Contingency recorded as a result of settlement | 8,500,000 | |||||||||
Estimated insurance recoveries | 4,000,000 | |||||||||
Reduction in litigation settlement contingency | $ 1,000,000 | 3,500,000 | ||||||||
Other expense | 4,500,000 | |||||||||
National Security Agreement | ||||||||||
Loss Contingencies [Line Items] | ||||||||||
Legal expenses | $ 400,000 | $ 1,700,000 | ||||||||
SAFE Note Litigation | ||||||||||
Loss Contingencies [Line Items] | ||||||||||
Alleged investment amount | $ 4,000,000 | |||||||||
Common stock issued (in shares) | 14,500 | |||||||||
SAFE Note Litigation | Pending Litigation | ||||||||||
Loss Contingencies [Line Items] | ||||||||||
Damages sought | $ 7,600,000 | |||||||||
Stephen J. Purcell | ||||||||||
Loss Contingencies [Line Items] | ||||||||||
Damages sought | $ 80,000 | |||||||||
Founder Litigation | ||||||||||
Loss Contingencies [Line Items] | ||||||||||
Payments for legal settlements | $ 100,000 |
Income Taxes - Schedule of Reco
Income Taxes - Schedule of Reconciliation of Effective Income Tax Rate (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Effective Income Tax Rate Reconciliation, Amount [Abstract] | ||
Tax provision (benefit) at U.S. statutory rate | $ (14,473) | $ (20,042) |
State income taxes, net of federal benefit | (6,694) | 11,113 |
Non-deductible expenses | 261 | (60) |
Change in value of equity instruments | (118) | (1,089) |
Deferred adjustments | (56) | (143) |
Other | (172) | 0 |
Research and development credits | (274) | (1,085) |
IRC Sec. 174 | 217 | 0 |
Uncertain tax positions | 69 | 276 |
Change in valuation allowance | 21,240 | 11,030 |
Income tax provision | $ 0 | $ 0 |
Effective Income Tax Rate Reconciliation, Percent [Abstract] | ||
Tax provision (benefit) at U.S. statutory rate | 21% | 21% |
State income taxes, net of federal benefit | 9.70% | (11.60%) |
Non-deductible expenses | (0.40%) | 0.10% |
Change in value of equity instruments | 0.20% | 1.10% |
Deferred adjustments | 0.10% | 0.20% |
Other | 0.30% | 0% |
Research and development credits | 0.40% | 1.10% |
IRC Sec. 174 | (0.30%) | 0% |
Uncertain tax positions | (0.10%) | (0.30%) |
Change in valuation allowance | (30.80%) | (11.60%) |
Effective Rate | 0% | 0% |
Income Taxes - Schedule of Defe
Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Deferred tax assets: | ||
Net operating loss carryforwards | $ 37,037 | $ 16,562 |
Start-up and Organization Costs | 16,913 | 16,965 |
Capitalized research and development credits | 10,943 | 17,922 |
Intangibles | 6,703 | 22 |
Stock-based compensation | 4,972 | 3,072 |
Research and development credits | 4,842 | 4,595 |
Operating lease obligations | 1,375 | 1,534 |
Accrued expenses and reserves | 621 | 1,710 |
Property and equipment | 233 | 173 |
Other | 1 | 1 |
Total deferred tax assets before valuation allowance | 83,640 | 62,556 |
Valuation allowance | (82,440) | (61,200) |
Total deferred tax assets | 1,200 | 1,356 |
Deferred Tax Liabilities: | ||
Operating lease right-of-use assets | (1,200) | (1,356) |
Total deferred tax liabilities | (1,200) | (1,356) |
Net deferred tax assets | $ 0 | $ 0 |
Income Taxes - Narrative (Detai
Income Taxes - Narrative (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 | May 31, 2022 |
Income Tax Examination [Line Items] | |||
Valuation allowance | $ 82,440 | $ 61,200 | |
Costs resulting in ending gross deferred tax asset | 83,600 | $ 84,300 | |
Operating lease obligations | 1,375 | 1,534 | |
Deferred tax liability | (1,200) | (1,356) | |
Federal | |||
Income Tax Examination [Line Items] | |||
Net operating loss carryforwards | 157,300 | 77,500 | |
Research and development credit carryforwards | 4,000 | 3,700 | |
State | |||
Income Tax Examination [Line Items] | |||
Net operating loss carryforwards | 55,900 | 46,400 | |
Research and development credit carryforwards | $ 3,100 | $ 3,000 |
Income Taxes - Schedule of Unre
Income Taxes - Schedule of Unrecognized Tax Benefits (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2023 USD ($) | |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |
Beginning balance | $ 1,712 |
Increases related to prior tax positions | (29) |
Increases related to current tax positions | 96 |
Ending balance | $ 1,779 |
Subsequent Events (Details)
Subsequent Events (Details) - USD ($) | 12 Months Ended | ||||||||||
Mar. 04, 2024 | Feb. 19, 2024 | Feb. 16, 2024 | Jan. 12, 2024 | Oct. 02, 2023 | Sep. 07, 2023 | Feb. 27, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Nov. 09, 2023 | Nov. 06, 2023 | |
Subsequent Event [Line Items] | |||||||||||
Aggregate cost | $ 4,000,000 | $ 5,000,000 | $ 10,000,000 | ||||||||
Number of warrants exercised on net basis (in shares) | 2,904,269 | ||||||||||
Exercise price (in dollars per share) | $ 2 | ||||||||||
Warrant term (years) | 5 years | ||||||||||
Service revenue | $ 3,089,000 | $ 299,000 | |||||||||
Common Class A | |||||||||||
Subsequent Event [Line Items] | |||||||||||
Number of shares sold (in shares) | 290,000 | 210,000 | |||||||||
Purchase price (in dollars per share) | $ 2 | $ 7.43 | |||||||||
Exercise price (in dollars per share) | $ 575 | ||||||||||
Subsequent Event | |||||||||||
Subsequent Event [Line Items] | |||||||||||
Aggregate cost | $ 4,000,000 | $ 4,000,000 | |||||||||
Subsequent Event | Experior Laboratories, Inc | |||||||||||
Subsequent Event [Line Items] | |||||||||||
Damages sought | $ 143,256 | ||||||||||
Subsequent Event | SpaceX Rideshare Service Agreement | D-Orbit SpA | |||||||||||
Subsequent Event [Line Items] | |||||||||||
Service revenue | $ 1,300,000 | ||||||||||
Subsequent Event | Common Class A | |||||||||||
Subsequent Event [Line Items] | |||||||||||
Number of shares sold (in shares) | 1,320,000 | 900,000 | |||||||||
Purchase price (in dollars per share) | $ 0.87 | $ 1.09 | |||||||||
January Warrants | Subsequent Event | |||||||||||
Subsequent Event [Line Items] | |||||||||||
Number of warrants exercised on net basis (in shares) | 3,687,000 | ||||||||||
Exercise price (in dollars per share) | $ 0.96 | ||||||||||
Warrant term (years) | 5 years | ||||||||||
Prefunded Warrants | |||||||||||
Subsequent Event [Line Items] | |||||||||||
Number of warrants exercised on net basis (in shares) | 1,710,000 | 462,948 | |||||||||
Exercise price (in dollars per share) | $ 0.00001 | $ 0.00001 | |||||||||
Prefunded Warrants | Subsequent Event | |||||||||||
Subsequent Event [Line Items] | |||||||||||
Number of warrants exercised on net basis (in shares) | 3,304,280 | 2,787,000 | |||||||||
November Warrants | |||||||||||
Subsequent Event [Line Items] | |||||||||||
Number of warrants exercised on net basis (in shares) | 5,808,538 | ||||||||||
Exercise price (in dollars per share) | $ 3.86 | ||||||||||
Warrant term (years) | 5 years | ||||||||||
March Warrants | Subsequent Event | |||||||||||
Subsequent Event [Line Items] | |||||||||||
Number of warrants exercised on net basis (in shares) | 4,624,280 | ||||||||||
Exercise price (in dollars per share) | $ 0.74 | ||||||||||
Warrant term (years) | 5 years |